Shreyaskumar R. Patel, M.D.

Peer-Reviewed Articles

1. Fabbroni, C, Johnston, EW, Sanfilippo, R, Strauss, DC, Bonvalot, S, Spalek, M, Van Houdt, WJ, Ford, SJ, Lee, KW, Salawu, A, Swallow, C, Bae, S, Gyorki, DE, Raut, CP, Mullinax, JE, Albertsmeier, M, Cananzi, FC, Konieczkowski, DJ, Grignol, V, Pennacchioli, E, Solli, P, Napolitano, A, Blasi, ED, Wilkinson, M, Stacchiotti, S, Tzanis, D, Rutkowski, P, Bouhadiba, T, Schrage, Y, Sherriff, J, Wang, J, Callegaro, D, Farma, JM, Fiore, M, Gervais, M, Gladdy, R, Nessim, C, Roland, CL, Cranmer, LD, Lee, TY, Patel, S, Von Mehren, M, Wagner, AJ, Sicklick, JK, Gronchi, A, Tseng, WW. Management of multifocal and metastatic retroperitoneal sarcoma. Cancer treatment reviews 143, 2026. e-Pub 2026. PMID: 41506129.
2. Patel RR, Feit J, Werling G, White NM, Bishop AJ, Lin PP, Valenzuela Perez RF, Lazar AJ, Benjamin RS, Patel SR, Ludwig J, Ravi V, Livingston JA, Zarzour MA, Conley A, Somaiah N, Araujo DM. Primary Synovial Sarcoma of the Abdomen and Pelvis. Am J Clin Oncol, 2025. e-Pub 2025. PMID: 41342607.
3. Traweek, R, Zoghbi, M, Segura Lazcano, R, Cope, B, Bishop, AJ, Farooqi, AS, Mitra, D, Yoder, A, Guadagnolo, BA, Ingram, D, Wani, K, Shamsutdinova, D, Lazar, A, Wang, W, Scally, CP, Keung, EZ, Torres, KE, Hunt, KK, Ratan, R, Livingston, JA, Nakazawa, MS, Araujo, DM, Patel, S, Ravi, V, Conley, AP, Zarzour, MA, Somaiah, N, Roland, CL, Nassif, EF. Hyalinization-based pathologic response and immune infiltration following neoadjuvant radiotherapy with or without immune-checkpoint blockade in localized undifferentiated pleomorphic sarcoma. ESMO Open 10(7), 2025. e-Pub 2025. PMID: 40561658.
4. Ginn, MP, Denu, RA, Ingram, D, Wani, K, Lazar, A, Harrison, DJ, Nakazawa, MS, Conley, AP, Patel, S, Livingston, JA. TFCP2 Fusion-Positive Rhabdomyosarcomas. Cancers 17(9), 2025. e-Pub 2025. PMID: 40361368.
5. Patel, R, Bishop, AJ, Lazar, A, Lin, PP, Benjamin, RS, Patel, S, Ludwig, JA, Ravi, V, Vaporciyan, AA, Araujo, DM. Primary Intrathoracic Synovial Sarcoma. Cancers 17(5), 2025. e-Pub 2025. PMID: 40075593.
6. Torres, MB, Leung, CH, Zoghbi, M, Segura Lazcano, R, Ingram, D, Wani, K, Keung, EZ, Zarzour, MA, Scally, CP, Hunt, KK, Conley, AP, Bishop, AJ, Guadagnolo, BA, Farooqi, AS, Mitra, D, Yoder, A, Nakazawa, MS, Araujo, DM, Livingston, A, Ratan, R, Patel, S, Ravi, V, Lazar, A, Roland, CL, Somaiah, N, Nassif, EF. Dedifferentiated liposarcomas treated with immune checkpoint blockade. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 40370451.
7. Giani C, Salawu A, Ljevar S, Denu RA, Napolitano A, Palmerini E, Connolly EA, Ogura K, Wong DD, Scanferla R, Rosenbaum E, Bajpai J, Li ZC, Bae S, D'Ambrosio L, Bialick S, Wagner AJ, Lee ATJ, Kosela-Paterczyk H, Baldi GG, Brunello A, Lee YC, Loong HH, Boikos S, Campos F, Cicala CM, Maki RG, Hindi N, Figura C, Almohsen SS, Patel S, Jones RL, Ibrahim T, Karim R, Kawai A, Carey-Smith R, Boyle R, Taverna SM, Lazar AJ, Demicco EG, JVMG B, Dei Tos AP, Fletcher C, Baumhoer D, Sbaraglia M, Schaefer IM, Miceli R, Gronchi A, Stacchiotti S. International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease. Am J Surg Pathol. e-Pub 2024. PMID: 39466087.
8. Patel RR, Delclos GL, DeSantis SM, Cannell MB, Lupo PJ, Bishop AJ, Lazar AJ, Lin PP, Benjamin RS, Patel SR, Ludwig J, Ravi V, Livingston JA, Somaiah N, Zarzour MA, Conley AP, Araujo DM. Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma?. Am J Clin Oncol. e-Pub 2024. PMID: 39224003.
9. Nakazawa MS, Silverman IM, Rimkunas V, Veloso A, Glodzik D, Johnson A, Ohsumi TK, Patel SR, Conley AP, Roland CL, Soliman PT, Beird HC, Wu CC, Ingram DR, Lazcano R, Song D, Wani KM, Lazar AJ, Yap TA, Wang WL, Livingston JA. Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas. Mol Cancer Ther 23(7):1057-1065, 2024. e-Pub 2024. PMID: 38561019.
10. Nasr LF, Zoghbi M, Lazcano R, Nakazawa M, Bishop AJ, Farooqi A, Mitra D, Guadagnolo BA, Benjamin R, Patel S, Ravi V, Araujo DM, Livingston A, Zarzour MA, Conley AP, Ratan R, Somaiah N, Lazar AJ, Roland C, Keung EZ, Nassif Haddad EF. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel) 16(9), 2024. e-Pub 2024. PMID: 38730715.
11. Denu RA, Joseph CP, Urquiola ES, Byrd PS, Yang RK, Ratan R, Zarzour MA, Conley AP, Araujo DM, Ravi V, Nassif Haddad EF, Nakazawa MS, Patel S, Wang WL, Lazar AJ, Somaiah N. Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. Cancers (Basel) 16(9), 2024. e-Pub 2024. PMID: 38730662.
12. Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer 5(4):625-641, 2024. e-Pub 2024. PMID: 38351182.
13. Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah N. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473266.
14. Nakazawa MS, Livingston JA, Zarzour MA, Bishop AJ, Ratan R, Ludwig JA, Araujo DM, Somaiah N, Ravi V, Nassif EF, Roland CL, Lazar AJ, Guadagnolo BA, Harrison DJ, Benjamin RS, Patel SR, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors 16:20363613241271669, 2024. e-Pub 2024. PMID: 39105190.
15. Denu RA, Yang RK, Lazar AJ, Patel SS, Lewis VO, Roszik J, Livingston JA, Wang WL, Shaw KR, Ratan R, Zarzour MA, Bird J, Raza S, Akdemir KC, Rodon Ahnert J, Subbiah V, Patel S, Conley AP. Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals TP53 mutation to be associated with worse outcomes. Clin Cancer Res 29(23):4844-4852, 2023. e-Pub 2023. PMID: 37747813.
16. Whiteway SL, Weiss AR, Ahmed SK, Allen-Rhoades WA, Avutu V, Cardona K, Davis LE, Davis EJ, Indelicato DJ, Isakoff MS, Janeway KA, Livingston JA, Patel SR, Reed DR, Riedel RF, Thornton KA, Kopp LM. Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group. J Adolesc Young Adult Oncol 12(5):792-793, 2023. e-Pub 2023. PMID: 36724495.
17. Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):1708-1718, 2023. e-Pub 2023. PMID: 37058010.
18. Nguyen J, Takebe N, Kummar S, Razak A, Chawla SP, George S, Patel SR, Keohan ML, Movva S, O'Sullivan Coyne G, Do K, Juwara L, Augustine B, Steinberg SM, Kuhlmann L, Ivy SP, Doroshow JH, Chen AP. Randomized Phase 2 Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. Clin Cancer Res 29(7):1200-1208, 2023. e-Pub 2023. PMID: 36302173.
19. Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med 12(4):4282-4293, 2023. e-Pub 2023. PMID: 36151848.
20. Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 29(2):401-409, 2023. e-Pub 2023. PMID: 36288393.
21. Bishop AJ, Amini B, Lin H, Raza SM, Patel S, Grosshans DR, Ghia A, Farooqi A, Guadagnolo BA, Mitra D, Akdemir KC, Lazar AJ, Wang WL, Alvarez-Breckenridge C, Bird J, Rhines LD, Somaiah N, Conley AP. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother 45(8):374-378, 2022. e-Pub 2022. PMID: 35943386.
22. Ravi V, Subramaniam A, Zheng J, Amini B, Trinh VA, Joseph J, Mennel RG, Bishop AJ, Sturgis EM, Goepfert RP, Yalamanchili S, Botello G, Stephen B, Piha-Paul SA, Patel AB, Lazar AJ, Conley AP, Benjamin RS, Patel SR, Futreal PA, Somaiah N, Naing A. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer 128(18):3383-3391, 2022. e-Pub 2022. PMID: 35792683.
23. Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, Salazar R, Barreto C, Chen H, Gite S, Haymaker C, Nassif EF, Bernatchez C, Mitra A, Livingston JA, Ravi V, Araujo DM, Benjamin R, Patel S, Zarzour MA, Sabir S, Lazar AJ, Wang WL, Daw NC, Zhou X, Roland CL, Cooper ZA, Rodriguez-Canales J, Futreal A, Soria JC, Wistuba II, Hwu P. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. e-Pub 2022. PMID: 35934010.
24. Avutu, V, Weiss, A, Reed, D, Ahmed, SK, Allen-Rhoades, W, Chen, YL, Davis, LE, Eaton, BR, Hawkins, DS, Indelicato, DJ, Patel, S, Randall, RL, Reinke, DK, Riedel, RF, Scharschmidt, TJ, Thornton, KA, Wang, D, Janeway, K, Kopp, LM. Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. Journal of adolescent and young adult oncology 11(3):328-332, 2022. e-Pub 2022. PMID: 34515544.
25. D'Angelo SP, Richards AL, Conley AP, Woo HJ, Dickson MA, Gounder M, Kelly C, Keohan ML, Movva S, Thornton K, Rosenbaum E, Chi P, Nacev B, Chan JE, Slotkin EK, Kiesler H, Adamson T, Ling L, Rao P, Patel S, Livingston JA, Singer S, Agaram NP, Antonescu CR, Koff A, Erinjeri JP, Hwang S, Qin LX, Donoghue MTA, Tap WD. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nat Commun 13(1):3477, 2022. e-Pub 2022. PMID: 35710741.
26. Bishop AJ, Zheng J, Subramaniam A, Ghia AJ, Wang C, McGovern SL, Patel S, Guadagnolo BA, Mitra D, Farooqi A, Reardon MJ, Kim B, Guha-Thakurta N, Li J, Ravi V. Cardiac Angiosarcomas: Risk of Brain Metastasis and Hemorrhage Warrants Frequent Surveillance Imaging and Early Intervention. Am J Clin Oncol 45(6):258-263, 2022. e-Pub 2022. PMID: 35588225.
27. Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, Catoe HW, Pang A, Subhawong TK, Amini B, Sweet K, Feister K, Malik K, Jagannathan J, Braschi-Amirfarzan M, Sheren J, Caldas Y, Moreno Tellez C, Rosenberg AE, Lazar AJ, Maki RG, Benedetto P, Cohen J, Trent J, Ravi V, Patel S, Wilky BA. Systemic chemotherapies retain anti-tumor activity in desmoid tumors independent of specific mutations in CTNNB1 or APC: A multi-institutional retrospective study. Clin Cancer Res. e-Pub 2022. PMID: 35180772.
28. Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
29. Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol 39(28):JCO2100217, 2021. e-Pub 2021. PMID: 34343033.
30. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, JVMG B, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer 127(16):2934-2942, 2021. e-Pub 2021. PMID: 33910263.
31. Jones RL, Herzog TJ, Patel SR, von Mehren M, Schuetze SM, Van Tine BA, Coleman RL, Knoblauch R, Triantos S, Hu P, Shalaby W, McGowan T, Monk BJ, Demetri GD. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med 10(11):3565-3574, 2021. e-Pub 2021. PMID: 33960681.
32. Gounder MM, Merriam P, Ratan R, Patel SR, Chugh R, Villalobos VM, Thornton M, Van Tine BA, Abdelhamid AH, Whalen J, Yang J, Rajarethinam A, Duh MS, Bobbili PJ, Huynh L, Totev TI, Lax AK, Agarwal S, Demetri GD. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer 127(8):1311-1317, 2021. e-Pub 2021. PMID: 33296083.
33. Chugh R, Ballman KV, Helman LJ, Patel S, Whelan JS, Widemann B, Lu Y, Hawkins DS, Mascarenhas L, Glod JW, Ji J, Zhang Y, Reinke D, Strauss SJ. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer 127(8):1301-1310, 2021. e-Pub 2021. PMID: 33289920.
34. Graff M, Justice AE, Young KL, Marouli E, Zhang X, Fine RS, Lim E, Buchanan V, Rand K, Feitosa MF, Wojczynski MK, Yanek LR, Shao Y, Rohde R, Adeyemo AA, Aldrich MC, Allison MA, Ambrosone CB, Ambs S, Amos C, Arnett DK, Atwood L, Bandera EV, Bartz T, Becker DM, Berndt SI, Bernstein L, Bielak LF, Blot WJ, Bottinger EP, Bowden DW, Bradfield JP, Brody JA, Broeckel U, Burke G, Cade BE, Cai Q, Caporaso N, Carlson C, Carpten J, Casey G, Chanock SJ, Chen G, Chen M, Chen YI, Chen WM, Chesi A, Chiang CWK, Chu L, Coetzee GA, Conti DV, Cooper RS, Cushman M, Demerath E, Deming SL, Dimitrov L, Ding J, Diver WR, Duan Q, Evans MK, Falusi AG, Faul JD, Fornage M, Fox C, Freedman BI, Garcia M, Gillanders EM, Goodman P, Gottesman O, Grant SFA, Guo X, Hakonarson H, Haritunians T, Harris TB, Harris CC, Henderson BE, Hennis A, Hernandez DG, Hirschhorn JN, McNeill LH, Howard TD, Howard B, Hsing AW, Hsu YH, Hu JJ, Huff CD, Huo D, Ingles SA, Irvin MR, John EM, Johnson KC, Jordan JM, Kabagambe EK, Kang SJ, Kardia SL, Keating BJ, Kittles RA, Klein EA, Kolb S, Kolonel LN, Kooperberg C, Kuller L, Kutlar A, Lange L, Langefeld CD, Le Marchand L, Leonard H, Lettre G, Levin AM, Li Y, Li J, Liu Y, Liu Y, Liu S, Lohman K, Lotay V, Lu Y, Maixner W, Manson JE, McKnight B, Meng Y, Monda KL, Monroe K, Moore JH, Mosley TH, Mudgal P, Murphy AB, Nadukuru R, Nalls MA, Nathanson KL, Nayak U, N'Diaye A, Nemesure B, Neslund-Dudas C, Neuhouser ML, Nyante S, Ochs-Balcom H, Ogundiran TO, Ogunniyi A, Ojengbede O, Okut H, Olopade OI, Olshan A, Padhukasahasram B, Palmer J, Palmer CD, Palmer ND, Papanicolaou G, Patel SR, Pettaway CA, Peyser PA, Press MF, Rao DC, Rasmussen-Torvik LJ, Redline S, Reiner AP, Rhie SK, Rodriguez-Gil JL, Rotimi CN, Rotter JI, Ruiz-Narvaez EA, Rybicki BA, Salako B, Sale MM, Sanderson M, Schadt E, Schreiner PJ, Schurmann C, Schwartz AG, Shriner DA, Signorello LB, Singleton AB, Siscovick DS, Smith JA, Smith S, Speliotes E, Spitz M, Stanford JL, Stevens VL, Stram A, Strom SS, Sucheston L, Sun YV. Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. Am J Hum Genet 108(4):564-582, 2021. e-Pub 2021. PMID: 33713608.
35. George S, Jones RL, Bauer S, Kang YK, Schöffski P, Eskens F, Mir O, Cassier PA, Serrano C, Tap WD, Trent J, Rutkowski P, Patel S, Chawla SP, Meiri E, Gordon M, Zhou T, Roche M, Heinrich MC, von Mehren M. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy. Oncologist 26(4):e639-e649, 2021. e-Pub 2021. PMID: 33453089.
36. Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan R. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat 186(3):871-882, 2021. e-Pub 2021. PMID: 33575859.
37. Boyce-Fappiano D, Guadagnolo BA, Ratan R, Wang WL, Wagner MJ, Patel S, Livingston JA, Lin PP, Diao K, Mitra D, Farooqi A, Lazar AJ, Roland CL, Bishop AJ. Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. Oncologist 26(3):250-260, 2021. e-Pub 2021. PMID: 33289298.
38. Traylor JI, Sheppard HE, Ravikumar V, Breshears J, Raza SM, Lin CY, Patel SR, DeMonte F. Computational Drug Repositioning Identifies Potentially Active Therapies for Chordoma. Neurosurgery 88(2):428-436, 2021. e-Pub 2021. PMID: 33017025.
39. Piha-Paul SA, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R, Subbiah V, Tannir N, Fu S, Naing A, Janku F, Karp DD, Patel S, Daw NC, Hong D, Meric-Bernstam F, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther 14:3037-3049, 2021. e-Pub 2021. PMID: 33994796.
40. Tarek N, Said R, Andersen CR, Suki TS, Foglesong J, Herzog CE, Tannir NM, Patel S, Ratan R, Ludwig JA, Daw NC. Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050651.
41. Martin-Broto J, Hindi N, Aguiar S, Badilla-González R, Castro-Oliden V, Chacón M, Correa-Generoso R, de Álava E, Donati DM, Eriksson M, Falla-Jimenez M, German G, Gobo Silva ML, Gouin F, Gronchi A, Haro-Varas JC, Jiménez-Brenes N, Kasper B, Lopes de Mello CA, Maki R, Martínez-Delgado P, Martínez-Said H, Martinez-Tlahuel JL, Morales-Pérez JM, Muñoz-Casares FC, Nakagawa SA, Ortiz-Cruz EJ, Palmerini E, Patel S, Moura DS, Stacchiotti S, Sunyach MP, Valverde CM, Waisberg F, Blay JY. Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. Oncologist. e-Pub 2020. PMID: 32888360.
42. Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JA. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32630797.
43. Groisberg R, Roszik J, Conley AP, Lazar AJ, Portal DE, Hong DS, Naing A, Herzog CE, Somaiah N, Zarzour MA, Patel S, Brown RE, Subbiah V. Genomics, morphoproteomics, and treatment patterns of alveolar soft part sarcoma patients and response to multiple experimental therapies. Mol Cancer Ther 19(5):1165-1172, 2020. e-Pub 2020. PMID: 32127467.
44. Kairemo K, Santos EB, Macapinlac HA, Patel S, Conley AP, Hong DS, Subbiah AV. Molecular Imaging with 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. Diagnostics (Basel) 10(3), 2020. e-Pub 2020. PMID: 32106426.
45. Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, Reuben A, Ingram D, Wang WL, Ju Z, Hong Leung C, Lin H, Zheng Y, Roszik J, Wang W, Patel S, Benjamin RS, Somaiah N, Conley AP, Mills GB, Hwu P, Gorlick R, Lazar A, Daw NC, Lewis V, Futreal PA. Immuno-genomic landscape of osteosarcoma. Nat Commun 11(1):1008, 2020. e-Pub 2020. PMID: 32081846.
46. Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma 2020:8363986, 2020. e-Pub 2020. PMID: 32565716.
47. Jones RL, Maki RG, Patel SR, Wang G, McGowan TA, Shalaby WS, Knoblauch RE, von Mehren M, Demetri GD. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer 125(24):4435-4441, 2019. e-Pub 2019. PMID: 31503332.
48. Bishop AJ, Bird JE, Conley AP, Roland CL, Moon BS, Satcher RL, Livingston JA, Patel S, Wang WL, Lazar AJ, Lewis VO, Lin PP, Guadagnolo BA. Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy with both Radiation and Surgery Improves Local Control. Am J Clin Oncol 42(10):744-748, 2019. e-Pub 2019. PMID: 31436747.
49. Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer 125(15):2610-2620, 2019. e-Pub 2019. PMID: 31173362.
50. Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer 125(14):2445-2454, 2019. e-Pub 2019. PMID: 31034598.
51. Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31096717.
52. Bishop AJ, Livingston JA, Araujo DM, Moon BS, Patel S, Wang WL, Lazar AJ, Roland CL, Guadagnolo BA. Extraskeletal Osteosarcomas: A Case Made for Combined Modality Local Therapy With Radiation and Surgery. Am J Clin Oncol 42(3):238-242, 2019. e-Pub 2019. PMID: 30614820.
53. van Maldegem A, Conley AP, Rutkowski P, Patel SR, Lugowska I, Desar IME, JVMG B, Gelderblom H. Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. Oncologist 24(1):110-116, 2019. e-Pub 2019. PMID: 30082492.
54. Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S. Corrigendum to "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy". Sarcoma 2019:7608743, 2019. e-Pub 2019. PMID: 31534435.
55. Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson PM, Pollock RE, Lev DC, Qiao W, McAleer MF, Benjamin RS, Patel S, Herzog CE, Daw NC, Feig BW, Lazar AJ, Hayes-Jordan A, Ludwig JA. Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clin Cancer Res 24(19):4865-4873, 2018. e-Pub 2018. PMID: 29871905.
56. Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer 18(1):913, 2018. e-Pub 2018. PMID: 30249211.
57. Conley AP, Trinh VA, Zobniw CM, Posey K, Martinez JD, Arrieta OG, Wang WL, Lazar AJ, Somaiah N, Roszik J, Patel SR. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol(4):1-6, 2018. e-Pub 2018. PMID: 30241159.
58. Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 4(6):814-820, 2018. e-Pub 2018. PMID: 29710216.
59. Choy E, Ballman K, Chen J, Dickson MA, Chugh R, George S, Okuno S, Pollock R, Patel RM, Hoering A, Patel S. SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Sarcoma 2018:2068517, 2018. e-Pub 2018. PMID: 30473623.
60. Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer 5(1):100, 2017. e-Pub 2017. PMID: 29254498.
61. Menegaz BA, Cuglievan B, Benson J, Camacho P, Lamhamedi-Cherradi SE, Leung CH, Warneke CL, Huh W, Subbiah V, Benjamin RS, Patel S, Daw N, Hayes-Jordan A, Ludwig JA. Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist. e-Pub 2017. PMID: 29212731.
62. Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 7(1):15963, 2017. e-Pub 2017. PMID: 29162825.
63. Reddy N, Moudgil R, Lopez-Mattei JC, Karimzad K, Mouhayar EN, Somaiah N, Conley AP, Patel S, Giza DE, Iliescu C. Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. Can J Cardiol 33(10):1335.e13-1335.e15, 2017. e-Pub 2017. PMID: 28822650.
64. Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 22(10):1271-1277, 2017. e-Pub 2017. PMID: 28710342.
65. Livingston JA, Bugano D, Barbo A, Lin H, Madewell JE, Wang WL, Lazar AJ, Tseng WW, Roland CL, Feig BW, Pollock R, Conley AP, Benjamin RS, Patel S, Somaiah N. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep 7(1):11836, 2017. e-Pub 2017. PMID: 28928422.
66. Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol 146(3):531-537, 2017. e-Pub 2017. PMID: 28651804.
67. Schvartsman G, Wagner MJ, Amini B, Zobniw CM, Trinh VA, Barbo AG, Lin HY, Wang WL, Conley AP, Ravi V, Araujo DM, Zarzour MA, Benjamin RS, Patel S, Somaiah N. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep 7(1):9519, 2017. e-Pub 2017. PMID: 28842575.
68. Charest-Morin R, Dirks MS, Patel S, Boriani S, Luzzati A, Fehlings MG, Fisher CG, Dekutoski MB, Williams R, Quraishi NA, Gokaslan ZL, Bettegowda C, Germscheid NM, Varga PP, Rhines LD, Forum Tumor AK. Ewing's Sarcoma of the Spine: Prognostic Variables for Survival and Local Control in Surgically Treated Patients. Spine (Phila Pa 1976). e-Pub 2017. PMID: 28837533.
69. Clarke MJ, Molina CA, Fourney DR, Fisher CG, Gokaslan ZL, Schmidt MH, Rhines LD, Fehlings MG, Laufer I, Patel SR, Rampersaud YR, Reynolds J, Chou D, Bettegowda C, Mendel E, Weber MH, Sciubba DM. Systematic review of the outcomes of surgical treatment of prostate metastases to the spine. Global Spine J 7(5):460-468, 2017. e-Pub 2017. PMID: 28811991.
70. Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martin-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist. e-Pub 2017. PMID: 28754721.
71. Davis LE, Janeway KA, Weiss AR, Chen YE, Scharschmidt TJ, Krailo M, Bender JLG, Kopp LM, Patel SR, Schwartz GK, Horvath LE, Hawkins DS, Chuk MK, Reinke DK, Gorlick RG, Randall RL. Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer. e-Pub 2017. PMID: 28493547.
72. Shankar GM, Clarke MJ, Ailon T, Rhines LD, Patel SR, Sahgal A, Laufer I, Chou D, Bilsky MH, Sciubba DM, Fehlings MG, Fisher CG, Gokaslan ZL, Shin JH. The role of revision surgery and adjuvant therapy following subtotal resection of osteosarcoma of the spine: a systematic review with meta-analysis. J Neurosurg Spine:1-8. e-Pub 2017. PMID: 28452631.
73. Teegavarapu PS, Rao P, Matrana MR, Cauley DH, Wood CG, Patel S, Tannir NM. Outcomes of Adults With Ewing Sarcoma Family of Tumors (ESFT) of the Kidney: A Single-Institution Experience. Am J Clin Oncol 40(2):189-193, 2017. e-Pub 2017. PMID: 25222071.
74. Schuetze SM, Bolejack V, Choy E, Ganjoo KN, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M, D'Amato G, Leu KM, Loeb DM, Forscher CA, Milhem MM, Rushing DA, Lucas DR, Chugh R, Reinke DK, Baker LH. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer 123(1):90-97, 2017. e-Pub 2017. PMID: 27696380.
75. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol, 2017. e-Pub 2017. PMID: 28988646.
76. Quintana RA, Banchs J, Gupta R, Lin HY, Raj SD, Conley A, Ravi V, Araujo D, Benjamin RS, Patel S, Vadhan-Raj S, Somaiah N. Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. Sarcoma 2017:7495914, 2017. e-Pub 2017. PMID: 29081684.
77. Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley AP. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res 7:11, 2017. e-Pub 2017. PMID: 28630682.
78. Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med 5(12):3437-3444, 2016. e-Pub 2016. PMID: 27882721.
79. Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep 6:35448, 2016. e-Pub 2016. PMID: 27748430.
80. Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget 7(39):64421-64430, 2016. e-Pub 2016. PMID: 27486883.
81. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. e-Pub 2016. PMID: 27589687.
82. Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH. Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. J Clin Oncol. e-Pub 2016. PMID: 27573658.
83. Goodwin CR, Abu-Bonsrah N, Bilsky M, Reynolds J, Rhines LD, Laufer I, Disch AC, Bozsodi A, Patel S, Gokaslan ZL, Sciubba DM, Bettegowda C. Clinical Decision Making: Integrating Advances in the Molecular Understanding of Spine Tumors. Spine (Phila Pa 1976). e-Pub 2016. PMID: 27488298.
84. Charest-Morin R, Boriani S, Fisher CG, Patel SR, Kawahara N, Mendel E, Bettegowda C, Rhines LD. Benign Tumours of the Spine: Has new Chemotherapy and Interventional Radiology Changed the Treatment Paradigm?. Spine (Phila Pa 1976). e-Pub 2016. PMID: 27488295.
85. Sciubba DM, Goodwin CR, Yurter A, Ju D, Gokaslan ZL, Fisher C, Rhines LD, Fehlings MG, Fourney DR, Mendel E, Laufer I, Bettegowda C, Patel SR, Rampersaud YR, Sahgal A, Reynolds J, Chou D, Weber MH, Clarke MJ. A systematic review of clinical outcomes and prognostic factors for patients undergoing surgery for spinal metastases secondary to breast cancer. Global Spine J 6(5):482-96, 2016. e-Pub 2016. PMID: 27433433.
86. Bhosale P, Wang J, Varma D, Jensen C, Patnana M, Wei W, Chauhan A, Feig B, Patel S, Somaiah N, Sagebiel T. Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?. J Comput Assist Tomogr. e-Pub 2016. PMID: 27454788.
87. Ravi V, Sanford EM, Wang WL, Ross JS, Ramesh N, Futreal A, Patel S, Stephens PJ, Miller VA, Ali SM. Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib. J Natl Compr Canc Netw 14(5):499-502, 2016. e-Pub 2016. PMID: 27160228.
88. Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387(10028):1629-37, 2016. e-Pub 2016. PMID: 26874885.
89. Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, Reinke DK, Baker LH. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer 122(6):868-74, 2016. e-Pub 2016. PMID: 26710211.
90. Wagner MJ, Livingston JA, Patel SR, Benjamin RS. Chemotherapy for Bone Sarcoma in Adults. J Oncol Pract 12(3):208-16, 2016. e-Pub 2016. PMID: 26962160.
91. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol 34(8):786-93, 2016. e-Pub 2016. PMID: 26371143.
92. Gupta R, Heshami N, Jay C, Ramesh N, Song J, Lei X, Rose EJ, Carter K, Araujo DM, Benjamin RS, Patel S, Nates JL, Ravi V. Predictors of survival in patients with sarcoma admitted to the intensive care unit. Clin Sarcoma Res 6:12, 2016. e-Pub 2016. PMID: 27437097.
93. Etchebehere EC, Hobbs BP, Milton DR, Malawi O, Patel S, Benjamin RS, Macapinlac HA. Assessing the role of (18)F-FDG PET and (18)F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. e-Pub 2015. PMID: 26631240.
94. Tseng WW, Zhou S, To CA, Thall PF, Lazar AJ, Pollock RE, Lin PP, Cormier JN, Lewis VO, Feig BW, Hunt KK, Ballo MT, Patel S, Pisters PW. Phase 1 adaptive dose-finding study of neoadjuvant Gemcitabine combined with radiation therapy for patients with high risk extremity and trunk soft-tissue sarcoma. Cancer. e-Pub 2015. PMID: 26177983.
95. Fan Z, Patel S, Lewis VO, Guadagnolo BA, Lin PP. Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?. Clin Orthop Relat Res. e-Pub 2015. PMID: 26197952.
96. Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, Mayfield J, Miller VA, Stephens PJ, Ross JS, Ali SM. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol 8(1):66. e-Pub 2015. PMID: 26062823.
97. Goldschlager T, Dea N, Boyd M, Reynolds J, Patel S, Rhines LD, Mendel E, Pacheco M, Ramos E, Mattei TA, Fisher CG. Giant cell tumors of the spine: has denosumab changed the treatment paradigm?. J Neurosurg Spine 22(5):526-33, 2015. e-Pub 2015. PMID: 25700239.
98. Benjamin RS, Wagner MJ, Livingston JA, Ravi V, Patel SR. Chemotherapy for bone sarcomas in adults: the MD anderson experience. Am Soc Clin Oncol Educ Book 35:e656-60, 2015. e-Pub 2015. PMID: 25993237.
99. Joseph J, Wang WL, Patnana M, Ramesh N, Benjamin R, Patel S, Ravi V. Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. Clin Sarcoma Res 5:22, 2015. e-Pub 2015. PMID: 26500758.
100. Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C. THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171(3):R111-22, 2014. e-Pub 2014. PMID: 24891137.
101. Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M. Towards a Drug Development Path that Targets Metastatic Progression in Osteosarcoma. Clin Cancer Res 20(16):4200-9, 2014. e-Pub 2014. PMID: 24803583.
102. Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP. Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. J Clin Oncol 32(15):1563-70, 2014. e-Pub 2014. PMID: 24638003.
103. Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, Staddon AP, Penel N, Piperno-Neumann S, Hendifar A, Lardelli P, Nieto A, Alfaro V, Chawla SP. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer 50(6):1137-47, 2014. e-Pub 2014. PMID: 24512981.
104. Mattei TA, Ramos E, Rehman AA, Shaw A, Patel SR, Mendel E. Sustained Long-term Complete Regression of a Giant Cell Tumor of the Spine after Treatment with Denosumab. Spine J. e-Pub 2014. PMID: 24534393.
105. Conter HJ, Gopalakrishnan V, Ravi V, Ater JL, Patel S, Araujo DM. Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience. Sarcoma 2014:375151, 2014. e-Pub 2014. PMID: 25024639.
106. Patel SR. Fifty years of advances in sarcoma treatment: moving the needle from conventional chemotherapy to targeted therapy. Am Soc Clin Oncol Educ Book:259-62, 2014. e-Pub 2014. PMID: 24857084.
107. Ganjoo KN, Patel S. The Treatment Outcome for Adult Patients with Ewing's Sarcoma. Curr Oncol Rep 15(4):372-7, 2013. e-Pub 2013. PMID: 23605781.
108. Dumont SN, Araujo DM, Munsell MF, Salganick JA, Dumont AG, Raymond KA, Linassier C, Patel S, Benjamin RS, Trent JC. Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med 2(4):553-63, 2013. e-Pub 2013. PMID: 24156028.
109. Patel S. Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway. Curr Oncol Rep 15(4):386-95, 2013. e-Pub 2013. PMID: 23605780.
110. Patel S. Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemother Pharmacol 72(2):277-86, 2013. e-Pub 2013. PMID: 23503753.
111. Ravi V, Patel S. Vascular sarcomas. Curr Oncol Rep 15(4):347-55, 2013. e-Pub 2013. PMID: 23852636.
112. Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, Schuetze S, Li J, Aymes A, Demetri GD. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 24(6):1703-9, 2013. e-Pub 2013. PMID: 23385197.
113. Yadav BS, Bansal A, Sharma SC, Javid SH, Anderson BO, Vaklavas C, Forero A, Ravi V, Patel S, Boudadi K, Chugh R, Morris GJ. A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer. Semin Oncol 40(2):135-44, 2013. e-Pub 2013. PMID: 23540738.
114. Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, Lazar AJ, Wang WL, Benjamin RS, Araujo DM. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res 3(1):7, 2013. e-Pub 2013. PMID: 23663788.
115. Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC, Patel SR, Lin PP, Guadagnolo A, Lòpez-Terrada D, Dei Tos AP, Lewis VO, Lev D, Pollock RE, Zagars GK, Benjamin RS, Madewell JE, Lazar AJ. Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. Clin Sarcoma Res 2(1):25, 2012. e-Pub 2012. PMID: 23272660.
116. Raj SD, Zhou X, Bueso-Ramos CE, Ravi V, Patel S, Benjamin RS, Vadhan-Raj S. Prognostic Significance of Elevated D-Dimer for Survival in Patients with Sarcoma. Am J Clin Oncol 35(5):462-7, 2012. e-Pub 2012. PMID: 21654313.
117. Richey SL, Rao P, Wood CG, Patel S, Tannir NM. Metastatic Extraosseous Ewing's Sarcoma (EES)/Primitive Neuroectodermal Tumor (PNET) of the Kidney: 8-Year Durable Response After Induction and Maintenance Chemotherapy. Clin Genitourin Cancer 10(3):210-2, 2012. e-Pub 2012. PMID: 22503609.
118. Patel S. Managing progressive disease in patients with GIST: Factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Cancer Treat Rev 38(5):467-72, 2012. e-Pub 2012. PMID: 22035971.
119. Chen LL, Chen X, Choi H, Sang H, Chen LC, Zhang H, Gouw L, Andtbacka RH, Chan BK, Rodesch CK, Jimenez A, Cano P, Jones KA, Oyedeji CO, Martins T, Hill HR, Schumacher J, Willmore C, Scaife CL, Ward JH, Morton K, Randall RL, Lazar AJ, Patel S, Trent JC, Frazier ML, Lin P, Jensen P, Benjamin RS. Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother 61(7):1113-24, 2012. e-Pub 2012. PMID: 22198309.
120. Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: Insights from the largest single-institutional experience. Cancer 118(11):2804-12, 2012. e-Pub 2012. PMID: 22006217.
121. Ravi V, Patel S. Adjuvant chemotherapy for soft tissue sarcomas. Surg Oncol Clin N Am 21(2):243-53, 2012. e-Pub 2012. PMID: 22365517.
122. Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, Reinke D, Chugh R, Benjamin RS, Helman LJ. Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist 17(3):321-e329, 2012. e-Pub 2012. PMID: 22665455.
123. Huh WW, Yuen C, Munsell M, Hayes-Jordan A, Lazar AJ, Patel S, Wang WL, Barahmani N, Okcu MF, Hicks J, Debelenko L, Spunt SL. Liposarcoma in children and young adults: A multi-institutional experience. Pediatr Blood Cancer 57(7):1142-6, 2011. e-Pub 2011. PMID: 21394894.
124. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ, Baker LH. R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research through Collaboration Study. J Clin Oncol 29(34):4541-7, 2011. e-Pub 2011. PMID: 22025149.
125. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 117(21):4939-47, 2011. e-Pub 2011. PMID: 21480200.
126. Fourney DR, Frangou EM, Ryken TC, Dipaola CP, Shaffrey CI, Berven SH, Bilsky MH, Harrop JS, Fehlings MG, Boriani S, Chou D, Schmidt MH, Polly DW, Biagini R, Burch S, Dekutoski MB, Ganju A, Gerszten PC, Gokaslan ZL, Groff MW, Liebsch NJ, Mendel E, Okuno SH, Patel S, Rhines LD, Rose PS, Sciubba DM, Sundaresan N, Tomita K, Varga PP, Vialle LR, Vrionis FD, Yamada Y, Fisher CG. Spinal Instability Neoplastic Score: An Analysis of Reliability and Validity From the Spine Oncology Study Group. J Clin Oncol 29(22):3072-7, 2011. e-Pub 2011. PMID: 21709187.
127. Huh WW, Guadagnolo BA, Munsell MF, Patel S, Lewis VO. Soft tissue sarcomas of the popliteal fossa: A single-institution retrospective review. Cancer 117(12):2728-34, 2011. e-Pub 2011. PMID: 21656751.
128. Patel S. Navigating Risk Stratification Systems for the Management of Patients With GIST. Ann Surg Oncol 18(6):1698-704, 2011. e-Pub 2011. PMID: 21213058.
129. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C. Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators. J Clin Endocrinol Metab 96(3):717-25, 2011. e-Pub 2011. PMID: 21190975.
130. Clark DW, Moore BA, Patel SR, Guadagnolo BA, Roberts DB, Sturgis EM. Malignant fibrous histiocytoma of the head and neck region. Head Neck 33(3):303-8, 2011. e-Pub 2011. PMID: 20629084.
131. Patel SR. Preface. Cancer Chemother Pharmacol 67 Suppl 1:S1, 2011. e-Pub 2011. PMID: 21116629.
132. Huh WW, Guadagnolo BA, Munsell MF, Patel S, Lewis VO. Soft tissue sarcomas of the popliteal fossa: a single-institution retrospective review. Cancer. e-Pub 2010. PMID: 21192061.
133. Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, Harrop JS, Fehlings MG, Boriani S, Chou D, Schmidt MH, Polly DW, Biagini R, Burch S, Dekutoski MB, Ganju A, Gerszten PC, Gokaslan ZL, Groff MW, Liebsch NJ, Mendel E, Okuno SH, Patel S, Rhines LD, Rose PS, Sciubba DM, Sundaresan N, Tomita K, Varga PP, Vialle LR, Vrionis FD, Yamada Y, Fourney DR. A Novel Classification System for Spinal Instability in Neoplastic Disease: An Evidence-Based Approach and Expert Consensus From the Spine Oncology Study Group. Spine (Phila Pa 1976) 35(22):E1221-9, 2010. e-Pub 2010. PMID: 20562730.
134. Pisters PW, Patel SR. Gastrointestinal stromal tumors: Current management. J Surg Oncol 102(5):530-8, 2010. e-Pub 2010. PMID: 20063363.
135. Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, Benjamin RS, Baker LH, through Collaboration SAFR. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial. Clin Cancer Res 16(19):4884-91, 2010. e-Pub 2010. PMID: 20724445.
136. Pandurengan RK, Dumont AG, Araujo DM, Ludwig JA, Ravi V, Patel S, Garber J, Benjamin RS, Strom SS, Trent JC. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol 21(10):2107-11, 2010. e-Pub 2010. PMID: 20348145.
137. Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med 153(6):358-67, 2010. e-Pub 2010. PMID: 20855800.
138. Trent JC, Patel SS, Zhang J, Araujo DM, Plana JC, Lenihan DJ, Fan D, Patel SR, Benjamin RS, Khakoo AY. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 116(1):184-192, 2010. e-Pub 2010. PMID: 19885836.
139. Rolston KV, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer 18(1):89-94, 2010. e-Pub 2010. PMID: 19387695.
140. Ganjoo KN, Demetri GD, Jacobs C, Patel S. Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec. Leuk Lymphoma 50(11):1882-4, 2009. e-Pub 2009. PMID: 19883316.
141. Gupta GR, Yasko AW, Lewis VO, Cannon CP, Raymond AK, Patel S, Lin PP. Risk of local recurrence after deltoid-sparing resection for osteosarcoma of the proximal humerus. Cancer 115(16):3767-73, 2009. e-Pub 2009. PMID: 19517468.
142. Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Myers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH. Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model. J Clin Oncol 27(19):3148-53, 2009. e-Pub 2009. PMID: 19451433.
143. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, Study Team ACOSOGIAG. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097-104, 2009. e-Pub 2009. PMID: 19303137.
144. Davis EC, Ballo MT, Luna MA, Patel SR, Roberts DB, Nong X, Sturgis EM. Liposarcoma of the head and neck: The University of Texas M. D. Anderson Cancer Center experience. Head Neck 31(1):28-36, 2009. e-Pub 2009. PMID: 18767171.
145. Rao G, Suki D, Chakrabarti I, Feiz-Erfan I, Mody MG, McCutcheon IE, Gokaslan Z, Patel S, Rhines LD. Surgical management of primary and metastatic sarcoma of the mobile spine. J Neurosurg Spine 9(2):120-8, 2008. e-Pub 2008. PMID: 18764743.
146. Guadagnolo BA, Zagars GK, Ballo MT, Patel SR, Lewis VO, Benjamin RS, Pollock RE. Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 70(3):760-5, 2008. e-Pub 2008. PMID: 17892916.
147. Guadagnolo BA, Zagars GK, Ballo MT, Patel SR, Lewis VO, Pisters PW, Benjamin RS, Pollock RE. Long-Term Outcomes for Synovial Sarcoma Treated with conservation Surgery and Radiotherapy. Int J Radiat Oncol Biol Phys 69(4):1173-80, 2007. e-Pub 2007. PMID: 17689031.
148. Armistead PM, Salganick J, Roh JS, Steinert DM, Patel S, Munsell M, El-Naggar AK, Benjamin RS, Zhang W, Trent JC. Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 110(10):2293-303, 2007. e-Pub 2007. PMID: 17896786.
149. Harb WJ, Luna MA, Patel SR, Ballo MT, Roberts DB, Sturgis EM. Survival in patients with synovial sarcoma of the head and neck: Association with tumor location, size, and extension. Head Neck 29(8):731-40, 2007. e-Pub 2007. PMID: 17274049.
150. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25(19):2755-63, 2007. e-Pub 2007. PMID: 17602081.
151. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C. We should desist using RECIST, at least in GIST. J Clin Oncol 25(13):1760-4, 2007. e-Pub 2007. PMID: 17470866.
152. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753-9, 2007. e-Pub 2007. PMID: 17470865.
153. Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, Lazar AA, Patel SR, Benjamin RS, Pollock RE. Optimizing treatment of desmoid tumors. J Clin Oncol 25(13):1785-91, 2007. e-Pub 2007. PMID: 17470870.
154. Lin PP, Jaffe N, Herzog CE, Costelloe CM, Deavers MT, Kelly JS, Patel SR, Madewell JE, Lewis VO, Cannon CP, Benjamin RS, Yasko AW. Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer 109(3):603-11, 2007. e-Pub 2007. PMID: 17177205.
155. Ballo MT, Zagars GK, Pollock RE, Benjamin RS, Feig BW, Cormier JN, Hunt KK, Patel SR, Trent JC, Beddar S, Pisters PW. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys 67(1):158-63, 2007. e-Pub 2007. PMID: 17084545.
156. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14(1):14-24, 2007. e-Pub 2007. PMID: 17072676.
157. Patel S, Keohan ML, Saif MW, Rushing D, Baez L, Feit K, DeJager R, Anderson S. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 107(12):2881-7, 2006. e-Pub 2006. PMID: 17109446.
158. Chirieac LR, Trent JC, Steinert DM, Choi H, Yang Y, Zhang J, Patel SR, Benjamin RS, Raymond AK. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer 107(9):2237-44, 2006. e-Pub 2006. PMID: 16998931.
159. Rolston KV, Manzullo EF, Elting LS, Frisbee-Hume SE, McMahon L, Theriault RL, Patel S, Benjamin RS. Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules. Cancer 106(11):2489-94, 2006. e-Pub 2006. PMID: 16628654.
160. Vorburger SA, Xing Y, Hunt KK, Lakin GE, Benjamin RS, Feig BW, Pisters PW, Ballo MT, Chen L, Trent J, Burgess M, Patel S, Pollock RE, Cormier JN. Angiosarcoma of the breast. Cancer 104(12):2682-8, 2005. e-Pub 2005. PMID: 16288486.
161. Jimenez C, Yang Y, Kim HW, Al-Sagier F, Berry DA, El-Naggar AK, Patel S, Vassilopoulou-Sellin R, Gagel RF. Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma. J Bone Miner Res 20(9):1562-8, 2005. e-Pub 2005. PMID: 16059628.
162. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64(17):5913-9, 2004. e-Pub 2004. PMID: 15342366.
163. Pisters PW, Patel SR, Prieto VG, Thall PF, Lewis VO, Feig BW, Hunt KK, Yasko AW, Lin PP, Jacobson MG, Burgess MA, Pollock RE, Zagars GK, Benjamin RS, Ballo MT. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol 22(16):3375-80, 2004. e-Pub 2004. PMID: 15310783.
164. Patel SR, Papadopolous N, Raymond AK, Donato M, Seong CM, Yasko AW, Lewis VO, Lin PP, Champlin R, Benjamin RS. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer 101(1):156-63, 2004. e-Pub 2004. PMID: 15222001.
165. Ballo MT, Zagars GK, Cormier JN, Hunt KK, Feig BW, Patel SR, Pisters PW. Interval between surgery and radiotherapy: effect on local control of soft tissue sarcoma. Int J Radiat Oncol Biol Phys 58(5):1461-7, 2004. e-Pub 2004. PMID: 15050324.
166. Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 98(12):2693-9, 2003. e-Pub 2003. PMID: 14669291.
167. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, Raymond AK, Cormier JN, Pisters PW, Pollock RE, Feig BW. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg 186(6):665-9, 2003. e-Pub 2003. PMID: 14672776.
168. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Evans HL. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 57(3):739-47, 2003. e-Pub 2003. PMID: 14529779.
169. Vadhan-Raj S, Patel SR, Bueso-Ramos C, Folloder J, Papadopolous N, Burgess A, Broemeling LD, Broxmeyer HE, Benjamin RS. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 21(16):3158-67, 2003. e-Pub 2003. PMID: 12915607.
170. Pisters PW, Ballo MT, Fenstermacher MJ, Feig BW, Hunt KK, Raymond KA, Burgess MA, Zagars GK, Pollock RE, Benjamin RS, Patel SR. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol 21(16):3092-7, 2003. e-Pub 2003. PMID: 12915599.
171. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res 9(7):2426-34, 2003. e-Pub 2003. PMID: 12855614.
172. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Evans HL. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys 56(2):482-8, 2003. e-Pub 2003. PMID: 12738324.
173. Patel SR, Beach J, Papadopoulos N, Burgess MA, Trent J, Jenkins J, Benjamin RS. Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 97(11):2848-52, 2003. e-Pub 2003. PMID: 12767099.
174. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer 97(10):2544-53, 2003. e-Pub 2003. PMID: 12733154.
175. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Evans HL. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 225 patients. Cancer 97(10):2530-43, 2003. e-Pub 2003. PMID: 12733153.
176. Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, Patel SR, Benjamin RS, Plager C, Papadopoulos NE, Burgess MA, Pollock RE, Feig BW. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 95(5):1120-6, 2002. e-Pub 2002. PMID: 12209699.
177. Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK, Garden AS, Benjamin RS. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer 95(2):377-88, 2002. e-Pub 2002. PMID: 12124838.
178. Bilimoria MM, Holtz DJ, Mirza NQ, Feig BW, Pisters PW, Patel S, Pollock RE, Benjamin RS, Papadopoulos NE, Plager C, Murphy A, Griffin JR, Burgess MA, Hunt KK. Tumor volume as a prognostic factor for sarcomatosis. Cancer 94(9):2441-6, 2002. e-Pub 2002. PMID: 12015769.
179. Ahmad SA, Patel SR, Ballo MT, Baker TP, Yasko AW, Wang X, Feig BW, Hunt KK, Lin PP, Weber KL, Chen LL, Zagars GK, Pollock RE, Benjamin RS, Pisters PW. Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol 20(2):521-7, 2002. e-Pub 2002. PMID: 11786582.
180. Porter GA, Cantor SB, Ahmad SA, Lenert JT, Ballo MT, Hunt KK, Feig BW, Patel SR, Benjamin RS, Pollock RE, Pisters PW. Cost-effectiveness of staging computed tomography of the chest in patients with T2 soft tissue sarcomas. Cancer 94(1):197-204, 2002. e-Pub 2002. PMID: 11815977.
181. Callister MD, Ballo MT, Pisters PW, Patel SR, Feig BW, Pollock RE, Benjamin RS, Zagars GK. Epithelioid sarcoma: results of conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 51(2):384-91, 2001. e-Pub 2001. PMID: 11567812.
182. Ballo MT, Zagars GK, Pisters PW, Feig BW, Patel SR, von Eschenbach AC. Spermatic cord sarcoma: outcome, patterns of failure and management. J Urol 166(4):1306-10, 2001. e-Pub 2001. PMID: 11547063.
183. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 92(5):1347-8, 2001. e-Pub 2001. PMID: 11571751.
184. Fleming JB, Cantor SB, Varma DG, Holst D, Feig BW, Hunt KK, Patel SR, Benjamin RS, Pollock RE, Pisters PW. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer 92(4):863-8, 2001. e-Pub 2001. PMID: 11550159.
185. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19(15):3483-9, 2001. e-Pub 2001. PMID: 11481354.
186. Portera CA, Jr, Ho V, Patel SR, Hunt KK, Feig BW, Respondek PM, Yasko AW, Benjamin RS, Pollock RE, Pisters PW. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 91(3):585-91, 2001. e-Pub 2001. PMID: 11169942.
187. Meric F, Milas M, Hunt KK, Hess KR, Pisters PW, Hildebrandt G, Patel SR, Benjamin RS, Plager C, Papadopolous NE, Burgess MA, Pollock RE, Feig BW. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol 18(19):3378-83, 2000. e-Pub 2000. PMID: 11013278.
188. Valenzuela RF, Kim EE, Seo JG, Patel S, Yasko AW. A revisit of MRI analysis for synovial sarcoma. Clin Imaging 24(4):231-5, 2000. e-Pub 2000. PMID: 11274890.
189. Fleming JB, Berman RS, Cheng SC, Chen NP, Hunt KK, Feig BW, Respondek PM, Yasko AW, Pollack A, Patel SR, Burgess MA, Papadopoulos NE, Plager C, Zagars G, Benjamin RS, Pollock RE, Pisters PW. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol 17(9):2772-80, 1999. e-Pub 1999. PMID: 10561352.
190. Pearlstone DB, Pisters PW, Bold RJ, Feig BW, Hunt KK, Yasko AW, Patel S, Pollack A, Benjamin RS, Pollock RE. Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer 85(1):85-92, 1999. e-Pub 1999. PMID: 9921978.
191. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 21(3):317-21, 1998. e-Pub 1998. PMID: 9626808.
192. Patel SR, Burgess MA, Papadopolous NE, Sidhu G, Gray R, Plager C, Jenkins J, Benjamin RS. Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest New Drugs 16(1):87-92, 1998. e-Pub 1998. PMID: 9740549.
193. Pisters PW, Patel SR, Varma DG, Cheng SC, Chen NP, Nguyen HT, Feig BW, Pollack A, Pollock RE, Benjamin RS. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 15(12):3481-7, 1997. e-Pub 1997. PMID: 9396401.
194. Worth LL, Jaffe N, Benjamin RS, Papadopoulos NE, Patel S, Raymond AK, Jia SF, Rodriguez C, Gano J, Gianan MA, Kleinerman ES. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma. Clin Cancer Res 3(10):1721-9, 1997. e-Pub 1997. PMID: 9815556.
195. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol 15(6):2378-84, 1997. e-Pub 1997. PMID: 9196153.
196. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, Johnston T, Papadopolous NE, Hittelman WN, Johnston DA, Yang TA, Paton VE, Cohen RL, Hellmann SD, Benjamin RS, Broxmeyer HE. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 126(9):673-81, 1997. e-Pub 1997. PMID: 9139552.
197. Patel SR, Linke KA, Burgess MA, Papadopoulos NE, Plager C, Jenkins J, Benjamin R. Phase II Study of Paclitaxel in Patients With Soft Tissue Sarcomas. Sarcoma 1(2):95-7, 1997. e-Pub 1997. PMID: 18521208.
198. Patel SR, Papadopoulos NE, Plager C, Linke KA, Moseley SH, Spirindonidis CH, Benjamin R. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer 78(4):741-4, 1996. e-Pub 1996. PMID: 8756366.
199. Patel SR, Plager C, Papadopoulos NE, Benjamin RS. Myxoid malignant fibrous histiocytoma: experience with chemotherapy. Am J Clin Oncol 18(6):528-31, 1995. e-Pub 1995. PMID: 8526198.
200. Patel SR, Winchester DJ, Benjamin RS. A 15-year experience with chemotherapy of patients with paraganglioma. Cancer 76(8):1476-80, 1995. e-Pub 1995. PMID: 8620426.
201. Vadhan-Raj S, Broxmeyer HE, Andreeff M, Bandres JC, Buescher ES, Benjamin RS, Papadopoulos NE, Burgess A, Patel S, Plager C, Hittelman WN, McAlister I, Garrison L, Williams DE. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood 86(6):2098-105, 1995. e-Pub 1995. PMID: 7662957.
202. Patel SR, Benjamin RS. Primary extraskeletal osteosarcoma--experience with chemotherapy. J Natl Cancer Inst 87(17):1331-3, 1995. e-Pub 1995. PMID: 7658488.
203. Patel SR, Burgess MA, Papadopoulos NE, Linke KA, Benjamin RS. Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol 18(2):161-3, 1995. e-Pub 1995. PMID: 7900708.
204. Patel SR, Burgess MA, Plager C, Papadopoulos NE, Linke KA, Benjamin RS. Myxoid liposarcoma. Experience with chemotherapy. Cancer 74(4):1265-9, 1994. e-Pub 1994. PMID: 8055448.
205. Vadhan-Raj S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, Arcenas A, Plager C, Kudelka AP, Hittelman WN, et al. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol 12(4):715-24, 1994. e-Pub 1994. PMID: 8151315.
206. Patel SR, Forman AD, Benjamin RS. High-dose ifosfamide-induced exacerbation of peripheral neuropathy. J Natl Cancer Inst 86(4):305-6, 1994. e-Pub 1994. PMID: 8158686.
207. Broxmeyer HE, Benninger L, Patel SR, Benjamin RS, Vadhan-Raj S. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol 22(1):100-2, 1994. e-Pub 1994. PMID: 7506671.
208. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 72(11):3244-7, 1993. e-Pub 1993. PMID: 8242548.
209. Benjamin RS, Legha SS, Patel SR, Nicaise C. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 31 Suppl 2:S174-9, 1993. e-Pub 1993. PMID: 8453693.
210. Laurie JA, Hahn RG, Therneau TM, Patel SR, Mailliard JA, Windschitl HE, Twito DI, Morton RF, Krook JE. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer 69(6):1440-4, 1992. e-Pub 1992. PMID: 1540881.
211. Patel SR, Buckner JC, Smithson WA, Scheithauer BW, Groover RV. Cisplatin-based chemotherapy in primary central nervous system germ cell tumors. J Neurooncol 12(1):47-52, 1992. e-Pub 1992. PMID: 1541978.
212. Patel SR, Kvols LK, Rubin J, O'Connell MJ, Edmonson JH, Ames MM, Kovach JS. Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Invest New Drugs 9(1):53-7, 1991. e-Pub 1991. PMID: 1709152.
213. Patel SR, Richardson RL, Kvols L, Zincke H. Observation after orchiectomy in clinical stage I nonseminomatous germ cell tumor of testis. Mayo Clinic experience. Am J Clin Oncol 13(5):379-81, 1990. e-Pub 1990. PMID: 2171316.
214. Ransom DT, Patel SR, Keeney GL, Malkasian GD, Edmonson JH. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer 66(6):1091-4, 1990. e-Pub 1990. PMID: 2400962.
215. Patel SR, Kvols LK, Hahn RG, Windschitl H, Levitt R, Therneau T. A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer 66(4):655-8, 1990. e-Pub 1990. PMID: 2201425.
216. Patel SR, Richardson RL, Kvols L. Synchronous and metachronous bilateral testicular tumors. Mayo Clinic experience. Cancer 65(1):1-4, 1990. e-Pub 1990. PMID: 2293856.
217. Patel SR, Kvols LK, Peterson DA, Gilbertson DT, Moertel CG, O'Dorisio TM. Comparison of the pharmacokinetics of octreotide injected at two subcutaneous sites. J Natl Cancer Inst 81(24):1926-9, 1989. e-Pub 1989. PMID: 2593172.
218. Abouharb S, Warneke CL, Ravi V, Ludwig JA, Lazar AJ, Patel S, Benjamin RS, Araujo DM. Synovial sarcoma: Evaluation of response to treatment with Gemcitabine and Docetaxel.
219. Stacchiotti S, Frezza AM, Demetri GD…Patel SR, …Gronchi A, Miceli R, Wagner AJ. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the minimum requirements for the evaluation of activity of systemic treatments.
220. Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland C, Conley AP, Zarzour MA, Livingston JA, Ratan R, Ludwig JA, Benjamin R, Patel S, Somaiah N. The PET/CT imaging as a diagnostic tool in identifying well-differentiated versus dedifferentiated liposarcoma. Oncologist.

Invited Articles

1. Groisberg R, Roszik J, Conley A, Patel S, Subbiah V. The role of NGS in sarcomas: Evolution from light microscope to molecular microscope. Curr Oncol Rep, 2017. e-Pub 2017.
2. Ratan R, Patel SR. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma. Curr Treatment Options, 2017. e-Pub 2017.
3. Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer, 2016. e-Pub 2016. PMID: 27434055.
4. Wagner MJ, Livingston JA, Patel SR, Benjamin RS. Chemotherapy for Bone Sarcomas in Adults. J. Oncol Prac, 2016. e-Pub 2016.
5. Ravi V, Patel S, Benjamin RS. Chemotherapy for Soft-Tissue sarcomas: Contemporary Approaches. Sarcoma Oncology: a Medical Approach, 2015. e-Pub 2015.
6. Benjamin RS, Wagner MJ, Livingston JA, Ravi V, Patel SR. Chemotherapy for Bone Sarcoma in Adults: The MD Anderson Experience. Am Soc Clin Oncol Educ Book:656-60, 2015. e-Pub 2015.
7. Patel S. Fifty years of advances in sarcoma treatment: moving the needle from conventional chemotherapy to targeted therapy. Am Soc Clin Oncol Educ Book:259-62, 2014. e-Pub 2014.
8. Patel S. Exploring Novel Therapeutic Targets in GIST: Focus on the P13K.Akt/mTOR Pathway. Curr Oncol Rep 15(4):386-96, 2013. e-Pub 2013.
9. Ravi V, Patel SR. Adjuvant chemotherapy for Soft-tissue Sarcomas. Surg Oncol Clin North Am 21:243-254, 2012. e-Pub 2012.
10. Ganjoo KN, Patel S. Current and emerging pharmacological treatments for gastrointestinal stromal tumour. Drugs 71(3):321-30, 2011. e-Pub 2011. PMID: 21319869.
11. Patel SR. Advances in Reducing Post-Surgical GIST Recurrence - Special Report. Clinical Oncology, 2010. e-Pub 2010.
12. Ganjoo KN, Patel SR. Trabectedin: an anticancer drug from the sea. Expert Opin Pharmacother 10(16):2735-43, 2009. e-Pub 2009. PMID: 19743937.
13. Yamazaki T, McLoughlin GS, Patel S, Rhines LD, Fourney DR. Feasibility and safety of en bloc resection for primary spine tumors: a systematic review by the Spine Oncology Study Group. Spine (Phila Pa 1976) 34(22 Suppl):S31-8, 2009. e-Pub 2009. PMID: 19829275.
14. Schuetze SM, Patel S. Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?. Oncologist 14(10):1003-12, 2009. e-Pub 2009. PMID: 19808770.
15. Collini P, Sorensen PH, Patel S, Blay JY, Issels RD, Maki RG, Eriksson M, del Muro XG. Sarcomas with spindle cell morphology. Semin Oncol 36(4):324-37, 2009. e-Pub 2009. PMID: 19664493.
16. Schuetze S, Patel SR. Should patients with High-risk soft-tissue sarcomas receive adjuvant chemotherapy. Oncologist 14(10):1003-12, 2009. e-Pub 2009.
17. Patel SR, Wong P. The efficacy of Imatinib in unresectable and metastatic GIST. US Oncology 5:61-64, 2009. e-Pub 2009.
18. Benjamin RS, Patel SR. Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy. Cancer Treat Res 152:355-63, 2009. e-Pub 2009. PMID: 20213401.
19. Benjamin RS, Patel SR. Pediatric and Adult osteosarcoma: Comparisons and contrasts in presentations and therapy, 2009. e-Pub 2009.
20. Kopp HG, Patel S, Brücher B, Hartmann JT. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. Am J Clin Dermatol 9(4):207-17, 2008. e-Pub 2008. PMID: 18572972.
21. Hartmann JT, Patel S. New drug developments for patients with metastatic soft tissue sarcoma. Curr Oncol Rep 7(4):300-6, 2005. e-Pub 2005. PMID: 15946590.
22. Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 7(4):293-9, 2005. e-Pub 2005. PMID: 15946589.
23. Steinert DM, Patel SR. Recent studies in novel therapy for metastatic sarcomas. Hematol Oncol Clin North Am 19(3):573-90, viii, 2005. e-Pub 2005. PMID: 15939198.
24. Hartmann JT, Patel SR. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 65(2):167-78, 2005. e-Pub 2005. PMID: 15631540.
25. Patel SR. Classification of Clear-cell Sarcoma. Curr Oncol Rep 6(4):307-308, 2004. e-Pub 2004. PMID: 15161585.
26. Patel SR. Molecular Testing for Synovial Sarcoma. Curr Omcol Rep 6(4):308, 2004. e-Pub 2004. PMID: 15161586.
27. Phan A, Patel S. Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol 4(6):433-9, 2003. e-Pub 2003. PMID: 14585224.
28. Patel SR, Zagars GK, Pisters PW. The follow-up of adult soft-tissue sarcomas. Semin Oncol 30(3):413-6, 2003. e-Pub 2003. PMID: 12870143.
29. Patel SR. Recent Advances in Treatment of Soft-Tissue Sarcomas. Expert Rev AntiCancer Ther 3(2):179-184, 2003. e-Pub 2003. PMID: 12781067.
30. Patel SR. Clinical Trials Report. Curr Oncol Rep 5:273, 2003. e-Pub 2003.
31. Cormier JN, Patel SR, Pisters PW. Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib. Curr Oncol Rep 4(6):504-9, 2002. e-Pub 2002. PMID: 12354363.
32. Patel SR. Systemic therapy for advanced soft-tissue sarcomas. Curr Oncol Rep 4(4):299-304, 2002. e-Pub 2002. PMID: 12044239.
33. Pisters PWT, Ballo MT, Patel SR. Chemoradiation for soft-tissue sarcomas. Ann Surg Oncol 9:535-542, 2002. e-Pub 2002.
34. Trent JC, Hannay JA, Li L, Patel SR, Benjamin RS, Pollock RE, Yu D. Inhibition of the PDGF-R by Gleevec (STI-571) in Human Rhabdomyosarcoma Cell Lines. Journal of the Princess Takamatsu Symposia 32:16-29, 2001. e-Pub 2001.
35. Patel SR, Benjamin RS. Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surg Oncol 9(2):67-70, 2000. e-Pub 2000. PMID: 11094325.
36. Patel SR. Radiation-induced sarcoma. Curr Treat Options Oncol 1(3):258-61, 2000. e-Pub 2000. PMID: 12057168.
37. Patel SR. Dose-Intensive chemotherapy for Soft-tissue Sarcomas. ASCO Educational Booklet:453-457, 2000. e-Pub 2000.
38. Patel SR. Clinical Trials Report. Curr Oncol Rep 2(6):485-487, 2000. e-Pub 2000.
39. Patel SR, Benjamin RS. New chemotherapeutic strategies for soft tissue sarcomas. Semin Surg Oncol 17(1):47-51, 1999. e-Pub 1999. PMID: 10402637.
40. Ahmed S, Patel SR, Feig BW. Treatment of recurrent soft-tissue sarcomas. Prob Gen Surg 16(3):73-83, 1999. e-Pub 1999.
41. Patel SR, Benjamin RS. Current status of chemotherapy for soft-tissue sarcomas. Indian J of Med and Ped Onc 18:70-79, 1997. e-Pub 1997.
42. Patel SR, Benjamin RS. Current status of chemotherapy for bone sarcomas. Indian J of Med and Ped Onc 18:5-8, 1997. e-Pub 1997.
43. Roth JA, Beech DJ, Pollock RE, Fidler IJ, Putnam JB, Patel SR, Benjamin RS. Treatment of the patient with lung metastases. Current Prob in Surg 33:881-960, 1996. e-Pub 1996.
44. Patel SR, Benjamin RS. Ifosfamide in sarcomas: is it a schedule-dependent drug?. Cancer Invest 14(3):290-1, 1996. e-Pub 1996. PMID: 8630693.
45. Jaffe N, Patel SR, Benjamin RS. Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Hematol Oncol Clin North Am 9(4):825-40, 1995. e-Pub 1995. PMID: 7490244.
46. Patel SR, Benjamin RS. Recent advances in the therapy of osteosarcoma and soft-tissue sarcomas. Internal Medicine-Clinical and Laboratory 3:1-4, 1995. e-Pub 1995.
47. Patel SR, Benjamin RS. Multidisciplinary management of Sarcomas. Hematol/Oncol Clin North Am 9:ix-xi, 1995. e-Pub 1995.
48. Patel SR, Benjamin RS. The Role of Chemotherapy in Soft Tissue Sarcomas. Cancer Control 1(6):599-605, 1994. e-Pub 1994. PMID: 10887013.
49. Patel SR, Armen T, Carrasco CH, Raymond AK, Ayala AG, Murray JA, Chawla SP, and Benjamin RS. Primary Chemotherapy in malignant fibrous histiocytoma of bone - updated UT MD Anderson Cancer Center Experience. Cancer Treatment - An Update:577-580, 1994. e-Pub 1994.
50. Patel SR, Benjamin RS. Standard and high dose chemotherapy for advanced soft tissue sarcomas. Ann Oncol 3 Suppl 2:S81-3, 1992. e-Pub 1992. PMID: 1622875.
51. Benjamin RS, Chawla SP, Carrasco CH, Raymond AK, Murray JA, Armen T, Patel S, Wallace S, Ayala A, Papadopoulos NE, et al. Preoperative chemotherapy for osteosarcoma with intravenous adriamycin and intra-arterial cis-platinum. Ann Oncol 3 Suppl 2:S3-6, 1992. e-Pub 1992. PMID: 1622860.

Review Articles

1. Czyz, M, Wensink, EG, Coimbra, B, Galgano, M, Patel, S, Redmond, KJ, Rutges, JP, Tan, JJ, Barzilai, O, Dea, N, Gasbarrini, A, Laufer, I, Lazary, A, Netzer, C, Reynolds, JJ, Rhines, LD, Sahgal, A, Fisher, CG, Verlaan, JJ. AO Spine Clinical Practice Recommendations. Global Spine Journal 15(4):1884-1889, 2025. e-Pub 2025. PMID: 40153520.
2. Kasper B, Baldini EH, Bonvalot S, Callegaro D, Cardona K, Colombo C, Corradini N, Crago AM, Dei Tos AP, Dileo P, Elnekave E, Erinjeri JP, Navid F, Farma JM, Ferrari A, Fiore M, Gladdy RA, Gounder M, Haas RL, Husson O, Kurtz JE, Lazar AJ, Orbach D, Penel N, Ratan R, Raut CP, Roland CL, Schut AW, Sparber-Sauer M, Strauss DC, Van der Graaf WTA, Vitellaro M, Weiss AR, Gronchi A, Working Group DT. Current Management of Desmoid Tumors: A Review. JAMA Oncol 10(8):1121-1128, 2024. e-Pub 2024. PMID: 38900421.
3. Banu MA, Raza SM, Amini M, Seaman S, Rubino F, Snyder R, Patel S, DeMonte F, Conley AP. The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol. Neurosurg Focus 56(5):E15, 2024. e-Pub 2024. PMID: 38691867.
4. Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. Cancer Treat Rev 112:102491, 2023. e-Pub 2023. PMID: 36502615.
5. Stacchiotti, S, Maria Frezza, A, Demetri, GD, Blay, JY, Bajpai, J, Baldi, GG, Baldini, EH, Benjamin, RS, Bonvalot, S, Bovée, JV, Callegaro, D, Casali, PG, D'Angelo, S, Davis, EJ, Dei Tos, AP, Demicco, EG, Desai, J, Dileo, P, Eriksson, M, Gelderblom, H, George, S, Gladdy, R, Gounder, M, Gupta, A, Haas, R, Hayes, AJ, Hohenberger, P, Jones, KB, Jones, RL, Kasper, B, Kawai, A, Kirsch, DG, Kleinerman, ES, Le Cesne, A, Maestro, R, Martin-Broto, J, Maki, RG, Miah, AB, Palmerini, E, Patel, S, Raut, CP, Razak, AR, Reed, D, Rutkowski, P, Sanfilippo, R, Sbaraglia, M, Schaefer, IM, Strauss, DC, Strauss, SJ, Tap, WD, Thomas, D, Trama, A, Trent, JC, Van Der Graaf, W, Van Houdt, WJ, Von Mehren, M, Wilky, B, Fletcher, CD, Gronchi, A, Miceli, R, Wagner, AJ. Retrospective observational studies in ultra-rare sarcomas. Cancer treatment reviews 110, 2022. e-Pub 2022. PMID: 36031697.
6. Blay JY, Palmerini E, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Chs CS, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden, Chacón M, Clara-Altamirano MA, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati DM, Dufresne A, Eriksson M, Farias-Loza M, Frezza AM, Frisoni T, Garcia-Ortega DY, Gerderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Hindi N, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes A, Lopes David BB, Lopez-Pousa A, Lutter G, Maki RG, Martinez-Said H, Martinez-Tlahuel JL, Mello CA, Morales Pérez JM, Moura DS, Nakagawa SA, Nascimento AG, Ortiz-Cruz EJ, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Santos TG, Scotlandi K, Mlg S, Soulé T, Stacchiotti S, Valverde CM, Waisberg F, Zamora Estrada E, Martin-Broto J. SELNET clinical practice guidelines for bone sarcoma. Crit Rev Oncol Hematol 174:103685, 2022. e-Pub 2022. PMID: 35460913.
7. Blay JY, Hindi N, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro-Sánchez CHS, Carvajal B, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden V, Chacón M, Clara M, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati D, Dufresne A, Eriksson M, Farias-Loza M, Fernandez P, Frezza AM, Frisoni T, Garcia-Ortega DY, Gelderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes David BB, Lopez-Pousa A, Lutter G, Martinez-Said H, Martinez-Tlahuel J, Mello CA, Morales Pérez JM, Moura David S, Nascimento AG, Ortiz-Cruz EJ, Palmerini E, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Salas R, Santos TTG, Scotlandi K, Soule T, Stacchiotti S, Valverde C, Waisberg F, Zamora Estrada E, Martin-Broto J. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treat Rev 102:102312, 2022. e-Pub 2022. PMID: 34798363.
8. Patel SR, Reichardt P. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. Cancer 127(13):2187-2195, 2021. e-Pub 2021. PMID: 33974733.
9. Ferrari A, Bleyer A, Patel S, Chiaravalli S, Gasparini P, Casanova M. The challenge of the management of adolescents and young adults with soft tissue sarcomas. Pediatr Blood Cancer, 2018. e-Pub 2018. PMID: 29493075.
10. Kumar R, Kumar M, Malhotra K, Patel S. Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment. Curr Oncol Rep 20(2):13, 2018. e-Pub 2018. PMID: 29492676.
11. Groisberg R, Roszik J, Conley A, Patel SR, Subbiah V. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. Curr Oncol Rep 19(12):78, 2017. e-Pub 2017. PMID: 29030741.
12. Ratan R, Patel SR. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?. Curr Treat Options Oncol 18(6):34, 2017. e-Pub 2017. PMID: 28534249.
13. Batista N, Tee J, Sciubba D, Sahgal A, Laufer I, Weber M, Gokaslan Z, Rhines L, Fehlings M, Patel S, Raja Rampersaud Y, Reynolds J, Chou D, Bettegowda C, Clarke M, Fisher C. Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer: Helping surgeons make decisions. J Clin Neurosci. e-Pub 2016. PMID: 27634496.
14. Schvartsman G, Wagner MJ, Zobniw CM, Trinh VA, Patel S, Somaiah N. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Curr Oncol Rep 18(8):49, 2016. e-Pub 2016. PMID: 27319943.
15. Ratan R, Patel SR. Chemotherapy for soft tissue sarcoma. Cancer. e-Pub 2016. PMID: 27434055.
16. Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 26(5):865-872, 2015. e-Pub 2015. PMID: 25070543.
17. Ravi V, Patel S, Benjamin RS. Chemotherapy for Soft-Tissue Sarcomas. Oncology (Williston Park) 29(1), 2015. e-Pub 2015. PMID: 25592207.
18. Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer 44(4):501-9, 2008. e-Pub 2008. PMID: 18234488.
19. Patel SR, Donato M, Papadopoulos NE, Plager C, Yasko AW, Champlin RE, Benjamin RS. Recent advances in systemic therapy of soft tissue sarcomas. Expert Rev Anticancer Ther 3(2):179-84, 2003. e-Pub 2003. PMID: 12722877.
20. Patel SR, Donato M, Papadopoulos NE, Plager C, Yasko AW, Champlin RE, Benjamin RS. Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas. Expert Opin Investig Drugs 11(12):1789-93, 2002. e-Pub 2002. PMID: 12457438.
21. Pisters PW, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol 9(6):535-42, 2002. e-Pub 2002. PMID: 12095968.
22. Cormier JN, Patel SR, Herzog CE, Ballo MT, Burgess MA, Feig BW, Hunt KK, Raney RB, Zagars GK, Benjamin RS, Pisters PW. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. Cancer 92(6):1550-5, 2001. e-Pub 2001. PMID: 11745234.
23. Patel SR. New agents in the treatment of soft-tissue sarcomas. Expert Opin Investig Drugs 9(7):1545-51, 2000. e-Pub 2000. PMID: 11060759.
24. Lynch HT, Fitzgibbons R, Jr, Chong S, Cavalieri J, Lynch J, Wallace F, Patel S. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum 37(3):260-7, 1994. e-Pub 1994. PMID: 8137673.
25. Patel SR, Kvols LK, Richardson RL. Familial testicular cancer: report of six cases and review of the literature. Mayo Clin Proc 65(6):804-8, 1990. e-Pub 1990. PMID: 2195242.
26. Patel SR, Richardson RL, Kvols L. Metastatic cancer to the testes: a report of 20 cases and review of the literature. J Urol 142(4):1003-5, 1989. e-Pub 1989. PMID: 2677407.

Other Articles

1. Blay, JY, Hindi, N, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sánchez, CH, Carvajal, B, Carvajal Montoya, A, Casavilca, S, Castro-Oliden, V, Chacón, M, Clara, M, Collini, P, Correa Genoroso, R, Costa, FD, Cuellar, M, Dei Tos, AP, Domínguez-Malagón, HR, Donati, D, Dufresne, A, Eriksson, M, Farias-Loza, M, Fernandez, P, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gelderblom, H, Gouin, F, Gómez-Mateo, MC, Gronchi, A, Haro-Varas, JC, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, Lopes David, BB, Pousa, AL, Lutter, G, Said, HM, Martínez-Tlahuel, J, Mello, CA, Morales-Pérez, JM, Moura David, S, Nascimento, AG, Ortiz-Cruz, EJ, Palmerini, E, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Salas, R, Santos, TT, Scotlandi, K, Soulé, T, Stacchiotti, S, Valverde Morales, C, Waisberg, F, Zamora Estrada, E, Martin-Broto, J Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312] (Cancer Treatment Reviews (2022) 102, (S0305737221001602), (10.1016/j.ctrv.2021.102312)). Cancer treatment reviews 115, 2023. PMID: 36796283.
2. Blay, JY, Palmerini, E, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, CHS, CS, Carvajal Montoya, A, Casavilca, S, Castro-Oliden, Chacón, M, Clara-Altamirano, MA, Collini, P, Correa Genoroso, R, Costa, FD, Cuellar, M, Dei Tos, AP, Domínguez-Malagón, HR, Donati, D, Dufresne, A, Eriksson, M, Farias-Loza, M, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gerderblom, H, Gouin, F, Gómez-Mateo, MC, Gronchi, A, Haro-Varas, JC, Hindi, N, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, Lopes, A, Lopes David, BB, Pousa, AL, Lutter, G, Maki, RG, Said, HM, Martínez-Tlahuel, J, Mello, CA, Morales-Pérez, JM, Moura, DS, Nakagawa, SA, Nascimento, AG, Ortiz-Cruz, EJ, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Santos, TG, Scotlandi, K, MLG, S, Soulé, T, Stacchiotti, S, Valverde Morales, C, Waisberg, F, Zamora Estrada, E, Martin-Broto, J Corrigendum to “SELNET clinical practice guidelines for bone sarcoma” Critical reviews in oncology/hematology, vol. 174 (2022), 1–10 (Critical Reviews in Oncology / Hematology (2022) 174, (S1040842822001093), (10.1016/j.critrevonc.2022.103685)). Critical Reviews in Oncology/Hematology 180, 2022. PMID: 36220678.

Editorials

1. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep, 2016.
2. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep, 2015.
3. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep, 2014.
4. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep, 2013.
5. Patel SR. Section Editor for Sarcoma Section, 2012.
6. Patel SR. Adjuvant Therapy for GIST. Cancer Chemother and Pharmacol Special Issue 67(1:S1), 2011.
7. Patel SR. Guest Editor, Adjuvant therapy for GIST. Cancer Chemother and Pharmacol – Special Issue, 2011.
8. Patel SR. Section Editor for Sarcoma Section. Current Oncology Rep(12):261-270, 2010.
9. Trent JC, Patel SR. Clinical update on adult and pediatric gastrointestinal stromal tumor. Preface. Hematol Oncol Clin North Am 23(1):xiii-xiv, 2009. PMID: 19248966.
10. Patel SR. Section Editor for Sarcoma Section. Current Oncology Rep 11:307-322, 2009.
11. Trent JC, Patel SR. Gastrointestinal Stromal Tumors. Hematology-Oncology Clinics of North America, 2009.
12. Patel SR. Section Editor for Sarcoma Section. Atlas of Cancer by Current Medicine:374-410, 2008.
13. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep(9):303-327, 2007.
14. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: Defying the dogma in Oncology. J Clin Oncol(24):11-12, 2006.
15. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep(8):291-310, 2006.
16. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep(7):285-311, 2005.
17. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep(6):307-327, 2004.
18. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep(5):273-303, 2003.
19. Patel SR. Section Editor for Sarcoma Section. Atlas of Cancer by Current Medicine:340-371, 2003.
20. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep(4):291-313, 2002.
21. Patel SR. Section Editor for Sarcoma Section. Curr Oncol Rep(2):485-510, 2000.
22. Patel SR, Benjamin RS. Sarcoma, Vol I & II. Hematology-Oncology Clinics of North America, 1995.
23. Legha SS, Patel SR. Musculoskeletal Oncology: A Multidisciplinary Approach. Cancer Bulletin 44:531-532, 1992.

Abstracts

1. Nassif EF, Beird H, Mitra A, Liu B, McBride K, Wang W, Ingram D, Wani K, Initiative Team EZKRT, Team PM, Zarzour A, Conley A, Araujo D, Livingston J, Ratan R, Patel S, Ravi V, Benjamin R, Lazar AJ, Roland CL, Futreal P, Somaiah N. Histology Specific Intratumoral B-Cell Biology in Alveolar Soft-Part Sarcomas (ASPS) in Response to Durvalumab-Tremelimumab (D-T). 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
2. Torres MB, Leung CH, Keung E, Feng C, Beird H, Zarzour A, Scally C, Hunt K, Conley A, Bishop A, Guadagnolo B, Farooqi A, Mitra D, Araujo D, Livingston A, Ratan R, Patel S, Ravi V, Lazar A, Roland CL, Somaiah N, Nassif EF. Dedifferentiated Liposarcomas Treated With Immune Checkpoint Blockade: The MD Anderson Experience. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
3. Livingston J, Cloutier J, Conley AP, Gorlick R, Benjamin RS, Posey K, Nassif E, Zarzour M, Araujo D, Ratan R, Ravi V, Somaiah N, Lin H, Leung CH, Lazar AJ, Lewis VO, Lin P, Amini B, Valenzuela RF, Patel S, Wang W. Chemotherapy and Prognostic Significance of Extent of Dedifferentiation in Dedifferentiated Parosteal Osteosarcoma. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
4. Roszik J, Denu RA, Nassif EF, Nakazawa M, Livingston JA, Ekdemir KC, Ratan R, Lazar AJ, Wang WL, Pestana R, Farooqi A, Roland C, Keung E, Ravi V, Somaiah N, Patel SR, Conley AP. TP53 ALTERATIONS IN SARCOMAS: AN ANALYSIS FROM THE AACR-GENIE DATABASE. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
5. Denu RA, Joseph CP, Urquiola ES, Byrd PS, Ratan R, Zarzour MA, Conley AP, Araujo D, Ravi V, Patel SR, Wang WL, Lazar AJ, Somaiah N. CLINICO-GENOMIC ANALYSIS OF KIT/PDGFRA/SDH WILD-TYPE GASTROINTESTINAL STROMAL TUMORS IDENTIFIES POTENTIAL DRIVER MUTATIONS. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
6. Subramaniam A, Wu CC, Beird H, Zhang J, Lazar AJ, Ingram D, Wani K, Bello A, Ali A Atkins M, Benjamin RS, Patel SR, Reardon MJ, Futreal PA, Ravi VConley AP, Ratan R, Somaiah N, Livingston JA, Zarzour MA, Araujo DM, Benjamin RS, Patel SR, Ravi V. PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
7. Gingrich A, Beird H, Chu R, Traweek R, Cope B, Keung EZ, Scally CP, Hunt KK, Torres KE, Roland CL, Prabhakara S, Initiative Team RT, Team PM, Futreal P, Bishop A, B Guadagnolo A, Mitra D, Farooqi A, Araujo D, Zarzour MA, Livingston JA, Conley A, Patel SR, Ravi V, Somaiah N, Lazar AJ, Ratan R, Nassif EF. Leiomyosarcoma intratumoral macrophage infiltrates are associated with distinct clinical and genomic presentations. 2023 CTOS Annual Meeting, 2023. e-Pub 2023.
8. Nakazawa M, Silverman IM, Rimkunas V, Veloso A, Glodzik D, Patel SR, Roland CL, Soliman PT, Beird H, Wu C, Ingram D, Segura RL, Wani KM, Lazar AJ, Yap TA, Wang WL, Livingston JA. Loss of the DNA repair gene RNase H2 and a unique subset of DDR-deficient leiomyosarcomas. 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
9. Thirasastr P, Lin HY, Nassif EF, Wang W, Araujo DM, Benjamin RS, Conley AP, Livingston J, Ludwig JA, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Clinical implications of recurring mutations in myxoid liposarcoma (MLS). 2023 ASCO Annual Meeting, 2023. e-Pub 2023.
10. Conley AP, Li L, Livingston JA, Bishop AJ, Grosshanes D, Ghia A, Mathew G, Khanduri I, Lang W, Bird J, Alvarez-Breckenridge C, Raza SM, Rhines LD, DeMonte F, Lazar A, Wang WL, Aarve A, Lin H, Roszik J, Amini B, Yevich S, Levy J, Sommer J, Freed D, Akdemir KC, Pudevali V, Patel SR. A Phase 2 Trial of Cetuximab for Patients with Locally Advanced Metastatic Chordoma. 2022 CTOS Annual Meeting, 2022. e-Pub 2022.
11. Somaiah N, Livingston JA, Ravi V, Lin HY, Amini B, Solis LM, Conley AP, Zarzour MA, Ludwig JA, Ratan R, Wang WL, Araujo DM, Patel SR, Roland CL, Lazar AJ, Gorlick RG, Parra ER, Haymaker CL. A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes. 2022 Annual ASCO Meeting, 2022. e-Pub 2022.
12. Thirasastr P, Joseph C, Araujo DM, Benjamin RS, Conley AP, Livingston JA, Ludwig JA, Patel SR, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Outcomes in late-line systemic treatment in GISTs: Does sequence matter?. 2022 Annual ASCO Meeting, 2022. e-Pub 2022.
13. Keung EZY, Nassif EF, Lin HY, Lazar AJ, Torres KE, Wang WL, Guadagnolo BA, Bishop AJ, Hunt K, Feig BW, Bird JE, Lewis VO, Ratan R, Patel SR, Zelazowska M, Liu B, McBride K, Wargo JA, Roland CL, Somaiah N. Randomized phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): Survival results after 2 years of follow-up and intratumoral B-Cell Receptor (BCR) correlates. 2022 Annual ASCO Meeting, 2022. e-Pub 2022.
14. Nakazawa M, Livingston J, Bishop AJ, Zarzour MA, Somaiah N, Ratan R, Gill JB, Urquiola E, Posey K, Guadagnolo BA, Gorlick RG, Benjamin RS, Patel S, Conley AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma (ARMS) patients on front-line therapies: An MD Anderson Cancer Center (MDACC) case series. 2022 Annual ASCO Meeting, 2022. e-Pub 2022.
15. Bishop AJ, Amini B, Lin H, Raza SM, Smith JT, Patel SR, Grosshans D, Farooqi A, Guadagnolo BA, Mitra D, Akdemir K, Lazar A, Wang WL, Bird JE, Rhines LD, Conley AP. Immune Checkpoint Inhibitors Provide Favorable Responses In Patients With Recurrent Chordoma. 2021 Annual CTOS Virtual Meeting, 2021. e-Pub 2021.
16. Pestana RC, Moyers J, Hamerschlak N, Roszik J, Sen S, Hong DS, Naing A, Herzog C, Fu S, Ravi V, Patel S, Livingston J, Somaiah N, Conley AP, Meric-Bernstam F, Subbiah V. Precision Oncology In Sarcoma Drug Development: Impact Of Biomarker Matching On Outcomes In Phase I Clinical Trials. 2021 Annual CTOS Virtual Meeting, 2021. e-Pub 2021.
17. Thirasastr P, Amini B, Lin H, Roland CL, Nassif EF, Zarzour A, Conley AP, Araujo DM, Keung EZ, Livingston J, Ratan R, Ludwig JA, IV, Benjamin RS, Zhou X, Patel S, Ravi V, Feig BW, Somaiah N. Retrospective Evaluation Of The Role Of Gemcitabine- Docetaxel In Well-Differentiated And Dedifferentiated Liposarcoma. 2021 Annual CTOS Virtual Meeting, 2021. e-Pub 2021.
18. Mitra A, Somaiah N, Conley AP, Amini B, Lin H, Sanchez BE, Garcia-Prieto C, Mathew G, Bernatchez C, Ravi V, Araujo D, Zarzour MA, Livingston JA, Roland CL, Daw N, Baguley J, Wang W, Beird H, Tate T, Haymaker C, Little LD, Gumbs C, Song X, Keung EZ, Zhang S, Gite S, Zhang J, Solis L, Tawbi H, Wang L, Patel S, Benjamin RS, Lazar AJ, Wistuba II, Futreal A. Immunogenomic correlates of response to combination immune checkpoint blockade in advanced sarcoma. 2021 AACR Annual Meeting, 2021. e-Pub 2021.
19. Kang Y, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel SR, Zhou Y, Mehren MV, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo M, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich M, Bauer S. Avapritinib Vs Regorafenib In Patients With Locally Advanced Unresectable Or Metastatic Gastrointestinal Stromal Tumor (Gist): Efficacy And Safety Data From Phase 3 Voyager Study. 2020 CTOS Annual Virtual Meeting, 2020. e-Pub 2020.
20. Topping RP, Keedy VL, Patel S, Riedel RF, Van Tine BA, Quill TA, Tap WD. Variance Between Experts And Community Practitioners In Treating Soft Tissue Sarcomas: Analysis Of An Online Decision Support Tool. 2020 CTOS Annual Vrtual Meeting, 2020. e-Pub 2020.
21. Nathenson MJ, Somaiah N, Hsu R, DeMaria P, Catoe H, Malik K, Harris C, Subhawong TK, Amini B, Jagannathan JP, Kevin Sweet MB, Feister K, Hu J, Sheren J, Rosenberg A, Lazar A, Ratan R, Ravi V, Patel SR, Maki R, Benedetto P, Cohen J, Trent J, Wilky BA. Association Of Ctnnb1 Mutation Subtypes With Response To Systemic Therapy In Patients With Desmoid Tumors: A Multi-Institutional Retrospective Study. 2020 CTOS Annual Virtual Meeting, 2020. e-Pub 2020.
22. Subramaniam A, Zheng J, Yalamanchili S, Coley AP, Ratan R, Sommaiah N, Livingston JA, Zarzour MA, Araujo DM, Benjamin RS, Patel SR, Ravi V. Modulation of YAP/TAZ by Statins to Improve Survival in Epitheloid Hemangioendothelioma (EHE). 2020 Annual ASCO Virtual Meeting, 2020. e-Pub 2020.
23. Kopp LM, Reed DR, Ahmed SK, Allen-Rhoades W, Avutu V, Chen YL, Davis LE, Eaton BR, Hawkins DS, Indelicato DJ, Patel SR, Randall RL, Reinke DK, Riedel RF, Scharschmidt T, Thornton KA, Wang D, Janeway KA, Weiss AR. Enrollment barriers of adolescents and young adults (AYA) on the non-chemotherapy arm of ARST1321. 2020 Virtual ASCO Meeting, 2020. e-Pub 2020.
24. Jones RL, Herzog TJ, Patel SR, von Mehren M, Schuetze S, Van Tine BA, Coleman RL, Triantos S, Hu P, Shalaby W, McGowan T, Monk BJ, Demetri GD. Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. 2020 Virtual ASCO Meeting, 2020. e-Pub 2020.
25. Somaiah N, Conley AP, Lin H, Amini B, Sabir SH, Araujo D, Benjamin RS, Livingston JA, Patel SR, Ratan R, Ravi V, Zarzour M, Wang WL, Taylor T, Roland C, Daw N, Futreal A, Lazar AJ, Wistuba I. A Phase II Multi-Arm Study of Durvalumab and Tremelimumab for Advanced or Metastatic Sarcomas. 2020 Virtual ASCO Meeting, 2020. e-Pub 2020.
26. Roland CR, Keung E, Lazar A, Torres KA, Wang WL, Guadagnoo A, Bishop AJ, Lin HY, Hunt K, Feig BW, Bird J, Lewis VO, Tawbi H, Ratan R, Patel SR, Wargo JA, Somaiah N. Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). 2020 Virtual ASCO Meeting, 2020. e-Pub 2020.
27. Gounder MM, Merriam P, Ratan R, Patel SR, Chugh R, Villalobos V, Thornton M, Van Tine VA, Abdelhamid AH, Whalen J, Yang J, Rajarethinam A, Duh MS, Bobbili PJ, Cavanaugh CL, Huynh Y, Totev T, Dmetri GD. Real-world Outcomes of Patients with Locally Advanced or Metastic Epitheliod Sarcoma. European Society for Medical Oncology (ESMO, 2019. e-Pub 2019.
28. Sen S, Pestana RC, Hess K, Hong DS, Subbiah IM, Conley A, Falchook GS, Benjamin RS, Patel S, Meric-Bernstam F, Subbiah V. Outcomes of geriatric sarcoma patients enrolled in phase I clinical trials. Proceedings of the 110th Annual Meeting of the American Association for Cancer Research, 2019. e-Pub 2019.
29. Wu C, Beird HC, Livingston JA, Cao, Advani, Ingram, Wang WL, Lazar AJ, Leung, Lin, Reuben, Roszik, Wang W, Patel S, Benjamin R, Gorlick R, Lewis V, Daw N, Futreal PA. Genome and transcriptome profiling of relapsed and metastatic osteosarcoma. ASCO Annual Meeting, 2018. e-Pub 2018.
30. Livingston JA, Beird HC, Wu C, Cao, Advani, Ingram, Wang WL, Lazar AJ, Leung, Lin, Reuben, Roszik, Wang W, Patel S, Benjamin R, Gorlick R, Lewis V, Futreal PA, Daw N. Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity. ASCO Annual Meeting, 2018. e-Pub 2018.
31. Parkes AM, Patel S, Leung CH, Lin HY, Conley AP, Somaiah N, Araujo DM, Zarzour MA, Livingston J, Ludwig JA, Ravi V, Benjamin RS, Ratan R. Systemic therapy regimen outcomes in metastatic phyllodes tumors of the breast. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
32. Kapoor GK, Li W, Sheng D, Knoblauch RE, Gormley M, Wang GC, Ricci DS, Smith MP, Motley C, s M, Maki RG, vonMehren M, Patel S, Demetri GD. Whole exome sequencing (WES) of metastatic leiomysarcoma (LMS) and liposarcoma (LPS) and correlation of genoic aberrations with clinical outcomes in the phase III randomized trial of travectedin (T) vs dacarbazine (D). 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
33. Wu C, Beird H, Livingston J, Cao S, Advani SM, Ingram D, Wang W, Lazar AJ, Reuben A, Zheng Y, Roszik J, Wang W, Gorlick RG, Benjamin RS, Patel S, Daw NC, Futreal A, Lewis VO. Genome and transcriptome profiling of relapsed and metastatic osteosarcoma. 2018 ASCO Annual Meeting, 2018. e-Pub 2018.
34. Somaiah N, Conley A, Espiridion BS, Lin H, Amini B, Ravi V, Araujo D, Benjamin R, Patel S, Zarzour A, Sabir S, Lazar AJ, Wang WL, Wistuba II, Hwu P. A phase II multi-arm study to test the efficacy of durvalumab and tremelimumab in multiple sarcoma subtypes. 2017 CTOS Annual Meeting, 2017. e-Pub 2017.
35. Groisberg R, Hong DS, Janku F, Piha-Paul SA, RAvi V, Benjamin RS, Patel S, Somaiah N, Conley AP, Herzog CE, Meric-Bernstam F, Subbiah V. Clinical next generation sequencing in sarcomas. J Clin Oncol, 2016. e-Pub 2016.
36. Conley AP, Huh WW, Roszik J, Harrison DJ, Hayes-Jordan AA, Kehr KA, Ratan R, Ravi V, Arauo DM, Zarzour MA, Ludwig JA, Wang WL, Benjamin RS, Patel S. Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies: An MD Anderson Cancer Center (MDACC) series. J Clin Oncol, 2016. e-Pub 2016.
37. Nathenson M, Conley AP, Ratan R, Zarzour MA, Somaiah N, Araujo DM, Patel S, Benjamin RS, Ravi V. Efficacy of front-line chemotherapy for recurrent/metastatic adenosarcoma of the uterus. J Clin Oncol, 2016. e-Pub 2016.
38. Chawla SP, Schoffski P, Blay J, Gelderblom H, Attia S, Chmielowski B, Van Tine BA, Jonathan C Trent II, Patel S, Wagner AJ, Viele JK, Chugh R, Cesne AL, Tinoco G, Sankhala KK, Heyburn JW, Falcone J, Schweizer C, Weil S, Maki RG. A Study of the Safety and Efficacy of the Combination of gemcitabine and Doxetaxel with Ontuzizumab (MORAb-004) in Metastatic Soft Tissue Sarcoma. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
39. Wagner MJ, MD, Livingston J, Ravi V, Gopalakrishnan V, Patel S, Lazar AJ, Ludwig J, Benjamin RS. Vincristine, doxorubicin, and ifosfamide (VAI) for initial treatment of ewing sarcoma,. Connective Tissue Oncology Society Annual Meeting, 2015. e-Pub 2015.
40. Patel S, von Mehren M, Reed D, Agulnik M, Kaiser P, Charlson J, Kraft A, Hamm J, Kamad A, Ryan C, Rushing D, Meyer C, Khokhar NZ, McCarthy S, Park YC, Knoblauch RE, Parekh TV, Maki RG, Demetri GD. Final Overall Survival analysis of the randomized phase 3 study of trabectedin or dacarbazine for the treatment of patients with advanced leiomyosarcoma or liposarcoma. European Cancer Congress, 2015. e-Pub 2015.
41. Burgess MA, Crowley J, Reinke DK, Riedel RF, George S, Movva S, Van Tine BA, Davis LE, Schuetze S, Hu J, Attia S, Priebat DA, Reed DR, D'Angelo SP, Okuno SH, Maki RG, Patel S, Baker LH, Tawbi HA. SARC 028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (P) in Patients (Pts) with Advanced Sarcomas. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
42. Davis EJ, Chugh R, Patel SR, with trabectedin SSARAOPWSTSTL. . A retrospective analysis of patients with soft tissue sarcoma treated long-term with trabectedin. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
43. Conley AP, Satcher RL, Wang WL, Lazar A, Fox P, Lin PP, Moon BS, Bird JE, Araujo D, Ravi V, Somaiah N, Patel SR, Benjamin RS, Lewis VO. Clinical Characteristics and Treatment Outcomes of Clear Cell Chondrosarcomas: An MD Anderson Cancer Center Experience. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
44. Grand’Maison A, Meis JM, Benjamin RS, Patel SR, Ravi V. Impact of chemotherapy on survival in primary gastrointestinal angiosarcomas. Connective Tissue Oncology Society Annual Meeting, 2015. e-Pub 2015.
45. Wagner MJ, Hess KR, Hong D, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Zinner R, Wheler J, Tsimberidou A, Patel S, Somaiah N, Ravi V, Benjamin RS, Meric-Bernstam, F, Subbiah V. Validation of the Royal Mersden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in anti-angiogenic early phase clinical trials at a Major Cancer Cente. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
46. Schoffski P, Maki R, Nguyen BB, Gelderblom H, Choy E, Grignani G, Camargo Vm Bauer S, Rs Y, Chawla S, Blay JY, D’Adamo D, Wang B, Chimelowski B, LeCesne A, Demetri G, Patel SR. Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma ADI). 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
47. Park H, Ignacio G, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Subbiah V, Tsimberiodu AM, Kaseb AO, Oki Y, Zinner RG, Patel SR, Michelle Fanale VMV, Medric-Bernstam F, Kurzrock R, Janku F. Phase 1 study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
48. Katz D, Lin H, Weaver N, Trent J, Hammerman A, Feldhamer I, Araujo D, Ravi V, Conley A, Wang W, Lazar A, Patel S, Benjamin R, Somaiah N. Predicting response to second-line sunitinib (SU) based on duration of treatment on front-line imatinib (IM) in patients with metastatic GIST. Connective Tissue Oncology Society Annual Meeting, 2015. e-Pub 2015.
49. Vadhan-Raj S, Ravi V Zhou X, Araujo D, Somaiah N, Conley A, Daniel M, Benjamin RS, Patel SR, Spasojevic I. Effects of Fosaprepitant (Fosa) on Ifosfamide (Iflex) Metabolism in Sacoma Patients (pts) Receiving Multi-day Chemotherapy (CT Regimen of Doxolrubicin (Dox) ad Ifex (AI): Randomized, Cross-over Study. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
50. Somaiah N, Beird H, Shaw K, Wang WL, Lazar A, Torres K, Ingram D, Conley A, Ravi V, Patel S, Subbiah V, Hwu P, Meric-Bernstam F, Futreal A, Hong D. Targeted next generation sequencing in well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): multiple gene amplifications but few mutations. 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
51. Demetri GD, von Mehren M, Jones ML, Hensley S, s S, Staddon AP, Millhem MM, Elias AD, Ganjoo KN, Tawbi HA, VanTine BA, Spira AI, Dean AP, Zhokhar NZ, Park YC, Knovlauch RE, Parekh TV, Maki RG, Patel S. A Ramdomized Phase III Study of Trabectedin (T) or Dacarbazine (D) for the treatment of patients (pts) with adanced liposarcoma (LPS or leiomyosarcoma (LMS). 2015 ASCO Annual Meeting, 2015. e-Pub 2015.
52. Ravi V, Wang W, Lazar AJ, Patel S, Benjamin RS. Metastatic potential of low and intermediate grade primary angiosarcomas of the breast: implications for neoadjuvant and adjuvant therapy. Connective Tissue Oncology Society Annual Meeting, 2015. e-Pub 2015.
53. Livingston J, Wagner MJ, Conley AP, Ravi V, Lewis VO, Lin PP, Patel S, Benjamin RS. Tailored post-operative therapy in adult osteosarcoma patients with poor necrosis: 30 years of treatment at MD Anderson cancer cente. Connective Tissue Oncology Society Annual Meeting, 2015. e-Pub 2015.
54. Gupta R, Ramesh N, Rose EJ, Carter K, Araujo DM, Benjamin RS, Patel S, Nates JL, Ravi V. Survival and outcomes of critically ill sarcoma patients admitted to the intensive care unit. J Clin Oncol 32(5s):supp, 2014. e-Pub 2014.
55. Somaiah N, Gomes DBD, Madewell JE, Wang WL, Conley AP, Ravi V, Araujo DM, Ludwig JA, Benjamin RS, Patel S. Defining the chemotherapy (CT) response in well-differentiated (WD) and dedifferentiated (DD) liposarcomas (LPS) of the retroperitoneum (RP): A tertiary referral cancer center experience. J Clin Oncol 32(5s):suppl, 2014. e-Pub 2014.
56. Vadhan-Raj S, Zhou X, Araujo DM, Somaiah N, Conley AP, Ravi V, Daniel M, Benjamin RS, Patel S. Effects of fosaprepitant (Fosa) administered as single dose versus two doses, on nausea/vomiting (N/V) in patients receivig multiday chemotherapy (CT) with a highly emetogenic regimen of doxorubicin and ifosfamide (AI): randomized cross-over study. ASCO 55th Annual Meeting, 2014. e-Pub 2014.
57. Subbiah V, Agarwal R, Janku F, Tsimberidou AM, Patel S, Benjamin RS, Ludwig HA, Anderson PM, Araujo DM, Ravi V, Conley AP Somaiah N, Wang WL, Naing A, Zinner R, Hong DS, Meric-Bernstam F. Diversity and heterogeneity in molecular analysis of advanced sarcomas: the clinical, regulatory, and financial challenge for drug development and precision medicine. J Clin Oncol, 2014. e-Pub 2014.
58. Somaiah N, Pollack SM, Wei W, Araujo D, Amaria RN, Mittendorf EA, Conley AP, Ravi V, Subbiah V, Benjamin RS, Patel S, Kenney R, Hsu F, Hwu P, Jones RL, Shapiro G, Kim JW, Block MM. Evaluating the safety and immunogenicity of ID-LV305, a third generation lentiviral vaccine in patients with NY-ESO-1 positive malignancies. 2014 Annual CTOS Meeting, 2014. e-Pub 2014.
59. Ravi V, Ramesh N, Patnana M, Conley AP, Somaiah N, Zarzour MA, Ingram D, Little L, Protopopov A, Lazar AJF, Araujo DM, Torres KE, Patel S, Zhang J, Ali SM, Miller VA, Stephens PJ, Benjamin RS, Hwu P, Futreal A. Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications. J Clin Oncol 32(5s):suppl, 2014. e-Pub 2014.
60. Ravi V, Ramesh N, Conley AP, Somaiah N, Subbiah V, Lazar A, Benjamin RS, Patel S. Prediciting survival using FDG-PET responses in patients with unclassified sarcoma. 2014 Annual CTOS Meeting, 2014. e-Pub 2014.
61. Abouharb S, Warneke CL, Ravi V, Ludwig JA, Lazar AJF, Patel S, Benjamin RS, Araujo DM. Synovial sarcoma: Evaluation of response to treatment with gemcitabine and docetaxel. J Clin Oncol 32(5s):suppl, 2014. e-Pub 2014.
62. Subbiah V, Patel S, Benjamin RS, Agarwal R, Janku F, Ludwig J, Anderson PM, Arujo D, Ravi V, Conley AP, Somaiah N, Naing A, Hong DS, Maric-Bernstam. Target-based therapeutic matching in early-phase clinical trials in patients with advanced sarcoma. 2014 Annual CTOS Meeting, 2014. e-Pub 2014.
63. Conley AP, Wang WL, Ravi V, Somaiah N, Subbiah V, Lazar A, Benjamin RS, Patel S. Clinical outcomes for patients with metastatic, malignant granular cell tumors treated with systemic therapies. 2014 Annual CTOS Meeting, 2014. e-Pub 2014.
64. Chawla S, Italiano A, Patel S, Hohenberger P, a S, Staddon A, Lardelli P, Nieto A, Kahatt C, Blay JY. Safety of trabectedin versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients with translocation-related sarcoma (TRS). Eurpoean Society for Medical Oncology, 2013. e-Pub 2013.
65. Dumont SN, Araujo DS, Dumont AG, Conley AP, Reynoso DG, Raymond K, Munsel MF, Patel S, Benjamin RS, Trent JC. ADULT RHABDOMYOSARCOMA: 239 PATIENTS FOLLOWED AT MD ANDERSON CANCER CENTER. 2012 CTOS Annual Meeting(899871), 2012. e-Pub 2012.
66. Blay, JV, Leahy MG, Nguyen BB, Patel SR, Santoro A, Hohenberger P, Demetri GD, Lardelli P, Perez I, Chawla SP. Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS). 2012 ASCO Annual Meeting, abstr TPS10101, 2012. e-Pub 2012.
67. Ravi V, Gupta R, Demicco EG, Araujo DM, Ludwig JA, Benjamin RS, Wang WW, Patel SR. Atypical vascular neoplasms and risk of development of angiosarcoma. 2012 ASCO Annual Meeting, abstract 1071, 2012. e-Pub 2012.
68. Vadhan-Raj S, Araujo DM, Trent JC, Zhou X, Ludwig JA, Ravi V, Chambers MS, Patel S, Benjamin RS. Phase II study of caphosol oral rinse for prevention of oral mucositis (OM) in sarcoma patiens (pts) receiving multi-cycle doxorubicin-based chemotherapy (CT): Randomized study with cross-over to palifermin for severe OM. ASCO 2012 Annual Mtg. Chicago, Illinois (#92822), 2012. e-Pub 2012.
69. Wang W, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent J, Patel SR, Lewis VO, Lin PP, Pollock RE, Guadagnolo A, Zagars G, Benjamin RS, Madewell JE, Lazar AJ. EXTENSIVE FATTY MATURATION CAN BE SEEN IN MYXOID LIPOSARCOMAS TREATED WITH NEOADJUVANT DOXORUBICIN AND IFOSAMIDE AND PRE-OPERATIVE RADIATION THERAPY. 2012 CTOS Annual Meeting(900478), 2012. e-Pub 2012.
70. Pappo A, Geoerger B, Crowley J, Brownstein C, Chawla S, Benjamin R, Helman L, Patel S. A PHASE II TRIAL OF R1507, A MONOCLONAL ANTIBODY TO THE INSULINLIKE GROWTH FACTOR-1 RECEPTOR (IGF1R) IN PATIENTS WITH RECURRENT OR REFRACTORY BONE AND SOFT TISSUE SARCOMAS EXCLUDING ESFT. 2012 CTOS Annual Meeting(Abstract 900715), 2012. e-Pub 2012.
71. Dumont SN, Trent JC, Salganick JA, Thall PF, Patel SR, Araujo DM, Benjamin RS. Efficacy and Safety of Low-Dose Protracted Ininotecan in Patients with Advanced Sarcomas: Results from a Phase II Study. 2011 Combined CTOS-MSTS Meeting(paper #14):90, 2011. e-Pub 2011.
72. Dumont SM, Trent JC, Patel S, Araujo DM, Dumont AG, Benjamin RS. A phase II study of low-dose protracted irinotecan in patients with advanced sarcomas. Journal of Clinical Oncology 29(15S):Abstract No 10064, 2011. e-Pub 2011.
73. Park MS, Patel S, Ravi V, Conley AP, Trent JC, Lazar AJF, Lev D, Wang X, Benjamin RS, Araujo, DM. The role of chemotherapy in advanced hemangiopericyoma/solitary fibrous tumor. Journal of Clinical Oncology 29(15S):Abstract No 10097, 2011. e-Pub 2011.
74. Ravi V, Yang J, Araujo DM, Park MS, Benjamin RS, Zhang W, Trent JC, Patel S. The role of E-cadherin expression in response and outcome in patients with leiomyosarcoma treated with chemotherapy. Journal of Clinical Oncology 29(15S):Abstract No. 10096, 2011. e-Pub 2011.
75. Pappo AS, Patel S, Crowley J, Reinke DK, Staddon AP, Kuenkele K, Chawla SP, Benjamin RS, Helman LJ, Baker LH. Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's Sarcoma family of tumors (ESFT): Results of a Phase II SARC Study. Journal of Clinical Oncology 28(15 Supplement):698s, 2010. e-Pub 2010.
76. Park MS, Patel SR, Trent JC, Wang W, Conley AP, Benjamin RS, Araujo DM. MULTIDISCIPLINARY MANAGEMENT OF PATIENTS WITH PRIMARY PULMONARY ARTERY SARCOMA (PPAS). 2010 CTOS Annual Meeting Abstract 899148, 2010. e-Pub 2010.
77. Dumont SN, Araujo DM, Dumont AG, Conley AP, Reynoso DG, Raymond K, Munsel MF, Patel S, Benjamin RS, Trent JC. Adult Rhabdomyosarcoma: 239 Patients Followed at MD Anderson Cancer Center. CTOS Oral Presentation, 2010. e-Pub 2010.
78. Schuetze SM, Wathen JK, Choy E, Ganjoo K, Chow W, Staddon A, Samuels B, Tawbi H, Patel S, Demetri G, Baker LH. SARC009, A PHASE II STUDY OF DASATINIB: RESULTS IN ALVEOLAR SOFT PART SARCOMA, CHONDROSARCOMA, CHORDOMA, EPITHELIOID SARCOMA OR SOLITARY FIBROUS TUMOR. 2010 CTOS Annual Meeting(898168), 2010. e-Pub 2010.
79. Stacchiotti S, Benjamin R, Blay JY, Judson I, Cesne A, Maki R, Palassini E, Patel S, Rutkowski P, Ray-Coquard I, Scurr M, Trent J, Ravi V, Casali PG. SUNITINIB IN ADVANCED ALVEOLAR SOFT PART SARCOMA (ASPS): A MULTI-INSTITUTIONAL RETROSPECTIVE CASE SERIES ANALYSIS WITHIN THE WORLD SARCOMA NETWORK. 2010 CTOS Annual Meeting(893840), 2010. e-Pub 2010.
80. Chen LL, Chen X, Gouw LG, Andtbacka RI, Jones KA, Ward JH, Randall R, Trent JC, Patel S, Benjamin RS. Combination of targeted therapy (imatinib) with immunotherapy to overcome drug resistance and tumor stem cells in gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology 2010 ASCO Annual Meeting Proceedings 28(15S):706s, 2010. e-Pub 2010.
81. Katz D, Boonsirikamchai P, Benjamin RS, Patel S, Ludwig JA, Trent JC, Xiao L, Ravi V, Choi H, Araujo DM. Efficacy of Neoadjuvant Doxorubicin and Ifosfamide (AI) in Myxoid/Round Cell Liposarcoma (MRCL): The M.D. Anderson Cancer Center Experience (MDACC). Journal of Clinical Oncology 2010 ASCO Annual Meeting Proceedings, 2010. e-Pub 2010.
82. Ravi V, Wang W, Araujo DM, Ludwig JA, Luke RJ, Lewis VO, Trent JC, Benjamin RS, Patel S. Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis. Journal of Clinical Oncology 2010 ASCO Annual Meeting Proceedings 28(15S):700s, 2010. e-Pub 2010.
83. Samuels BL, Tap WD, Patel S, Von Mehren M, Hamm JT, Kaiser PE, Schuetz S, Li J, Bayever E, Demetri GD. Trabectedin (TR) as single agent for advanced soft tissue sarcomas (STS) failing standard of care: Interim analysis of 1,400 patients (pts) in an expanded access program study. Journal of Clinical Oncology 2010 ASCO Annual Meeting Proceedings 28(15S):704s, 2010. e-Pub 2010.
84. Huh W, Guadagnolo B, Munsell MF, Patel S, Lewis VO. SOFT TISSUE SARCOMAS OF THE POPLITEAL FOSSA. 2010 CTOS Annual Meeting:Abstract 890614, 2010. e-Pub 2010.
85. Park MS, Patel S, Trent JC, Wang W, Conley AP, Benjamin RS, Araujo DM. Multidisciplinary management of patients with primary pulmonary artery sarcoma (PPAS). Journal of Clinical Oncology 2010 ASCO Annual Meeting Proceedings 28(15S):e20501, 2010. e-Pub 2010.
86. Vadhan-Raj S, Trent J, Araujo DM, Patel S, Zhou X, Benjamin RS. Evaluation of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): Results of a phase I/II study. J Clin Oncol 27, 2009 ASCO Annual Meeting(e20616), 2009. e-Pub 2009.
87. Conley AP, Araujo D, Ludwig L, Ravi V, Samuels BL, Choi H, Thall PF, Patel S, Benjamin R, Trent J. A Randomized phase II study of periofosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). 2009 ASCO Annual Meeting, 2009. e-Pub 2009.
88. Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Choi H, Benjamin RS, Araujo DM. Combination therapy with temozolamide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor. ASCO 2008, Oral Presentation, Abstract #10512, 2008. e-Pub 2008.
89. Vadhan-Raj S, Trent JC, Patel SR, Araujo DM, Ludwig JA, Bailey D, Zhou X, Gillenwater A, El-Naggar A, Benjamin RS. Randomized, double-blind, placebo-controlled study of palifermin for the prevention of mucositis in patients receiving doxorubicin-based chemotherapy. ASCO 2008, Abstract #9547, 2008. e-Pub 2008.
90. Khakoo AY, Steinert DM, Patel SR, Plana JC, Ludwig J, Benjamin RS, Trent JC. Rare incidence of congestive heart failure (CHF) in gastrointestinal stromal tumor (GIST) and other sarcoma patients (pts) receiving imatinib mesylate (IM) therapy. Proc Am Soc Clin Oncol(25):551, 2007. e-Pub 2007.
91. McAuliffe J, Lazar A, Steinert D, Patel SR, Benjamin RS, Trent JC. Kit-stem cell factor (kit ligand) axis in GIST patients treated with imatinib. Proc Am Soc Clin Oncol(25):556, 2007. e-Pub 2007.
92. Vadhan-Raj S, Bueso-Ramos C, Trent JC, Patel SR, Zhou X, Benjamin RS, Meyers CA. Elevated interleukin-6 levels correlation with anemia, symptom burden, and neurocognitive deficit in cancer patients receiving chemotherapy: Effects of darbepoetin-alfa administered once per cycle for prevention of anemia. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):19505, 2007. e-Pub 2007.
93. Chugh R, Maki RG, Thomas DG, Reinke D, Wathen JK, Patel SR, Priebat DA, Pa M, Benjamin RS, Baker LH. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. Proc Am Soc Clin Oncol(24):523, 2006. e-Pub 2006.
94. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Chuslip C. Once per cycle combination of long-acting hematopoietic growth factors (HGFs) pegfilgrastim and darbepoetin alfa (Peg-G + DPO) to redue multi-lineage hematopoietic toxicity of chemotherapy with doxorubicin and ifosfamide (AI) in patients with sarcoma. Proc Am Soc Clin Oncol(24):520, 2006. e-Pub 2006.
95. Maki RG, Hensley ML, Wathen JK, Patel SR, Pievat DA, Okuno S, Reinke D, Thall PF, Benjamin RS, Baker LH. A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). Proc Am Soc Clin Oncol(24):523, 2006. e-Pub 2006.
96. Kleinbaum EP, Chen LL, Lazar A, Strong L, Zhang W, Choi H, Benjamin RS, Patel SR, Trent JC. Familial gastrointestinal stromal tumor with homo-/hemizygous kit exon 11 deletion: Genotypic, histopathologic, radiographic, and therapeutic findings. Proc Am Soc Clin Oncol(24):526, 2006. e-Pub 2006.
97. Lin EH, Li Y, Trent JC, Patel S, Burgess MA, Steinert DM, Benjamin RS, Li D, Chen LL. Quantitative real time-PCR of CD133 mRNA: A potential surrogate angiogenic marker of response for patients with metastatic sarcoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 24(18S), 2006. e-Pub 2006.
98. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Chuslip C. Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings 24(No. 18S):Abstract 9506, 2006. e-Pub 2006.
99. Trent JC, Choi H, Lazar A, Davis D, Hunt K, Patel S, Pollock RE, and Benjamin RS. Apoptotic and Antiangiogenic Activity of Imatinib in Gastrointestinal Stromal Tumor (GIST). Proc Am Soc Clin Oncol(24), 2005. e-Pub 2005.
100. Vadhan-Raj S, Trent J, Burgess MA, Patel S, Collard ML, Zachariah G, Hangoc G, Johnson M, Broxmeyer HE, Benjamin RS. Once per cycle combination of long-acting hematopoietic growth factors (HGFs) pegfilgrastim and darbepoetin alfa (Peg-G + DPO) to redue multi-lineage hematopoietic toxicity of chemotherapy with doxorubicin and ifosfamide (AI) in patients with sarcoma. Proc Am Soc Clin Oncol(23):784s, 2005. e-Pub 2005.
101. Steinert DM, Blakely LJ, Patel SR, Burgess MA, Chen LL, Trent JC, Raymond AK, Benjamin RS. Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy. Proc Am Soc Clin Oncol(23):825, 2004. e-Pub 2004.
102. Pisters PW, Ballo MT, Bekele N, Thall PF, Feig BW, Lin P, Cormier JN, Benjamin RS, Patel SR. Phase I trial using toxicity severity weights for dose finding of gemcitabine combined with radiation therapy and subsequent surgery for patients with extremity and trunk soft tissue sarcomas. Proc Am Soc Clin Oncol(23):816, 2004. e-Pub 2004.
103. Salganick JA, Oyedeji CO, Patel SR, Burgess MA, Chen LL, Benjamin RS, Trent, JC. Differential sensitivity of rhabomyosarcoma cell line clones to EGF receptor inhibition with gefitinib. Proc Am Soc Clin Oncol(23):814, 2004. e-Pub 2004.
104. Rolston K, Frisbee-Hume S, Manzullo E, Theriault R, Patel S, Benjamin RS. Once daily, oral, outpatient therapy for low-risk febrile neutropenic patients. 15th Intl. MASCC symposium, 2003. e-Pub 2003.
105. Choi H, Charnsangavej C, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computerized tomography and positron emission tomography in patients with metastatic GIST treated at a single institution with imatinib mesylate. Proc Am Soc Clin Oncol(22):819, 2003. e-Pub 2003.
106. Trent JC, Burgess MA, Chen L, Jenkins J, Beach JL, Benjamin RS, Patel SR. A two-arm phase 2 study of temozolomide in GIST and other soft-tissue sarcomas. Proc Am Soc Clin Oncol(22):821, 2003. e-Pub 2003.
107. Trent JC, Hannay JA, Buchdunger E, Li L, Patel S, Benjamin RS, Pollock RE, Yu D. Inhibition of PDGF receptor tyrosine kinase a by STI571 (Gleevec) in human soft-tissue sarcoma cell lines. Cancer Res(43):1084, 2002. e-Pub 2002.
108. Patel SR, Donato M, Papadopoulos NE, Plager C, Yasko AW, Champlin RE, Benjamin RS. A phase 2 study of cisplatin, ifosfamide and adriamycin with peripheral blood stem cell (PBSC) reinfusions in patients (pts) with untreated bone sarcomas with poor prognosis. Proc Am Soc Clin Oncol(21):409a, 2002. e-Pub 2002.
109. Patel SR, Hays C, Papadopoulos NE, Burgess MA, Linke KA, Plager C, Benjamin RS. Pilot study of high-dose ifosfamide + G-CSF in patients with bone and soft-tissue sarcomas. Proc Am Soc Clin Oncol 14:516, 1995. e-Pub 1995.
110. Kleinerman, Gano J, Raymond AK, Corpron C, Benjamin R, Papadopolous N, Patel S, Jaffe N. Phase II study if recombinant IL-1 alfa plus etoposide in relapsed osteosarcoma. Proc Am Soc Clin Oncol 14:518, 1995. e-Pub 1995.
111. Munnangi P, King BL, Chiang Y, Conley AP, Araujo DM, Livingston J, Ludwig JA, Nakazawa M, Nassif Haddad EF, Ravi V, Ratan R, Zarzour MA, Patel S, Torres KE, Somaiah N. Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST). 2024 ASCO Annual Meeting.
112. Gingrich A, Beird H, Segura RL, Denu R, Nakazawa M, Ratan R, Livingston J, Zarzour MA, Conley AP, Somaiah N, Araujo DM, Patel S, Roland CL, Futreal A, Lazar AJ, Keung EZ, Nassif Haddad EF, Initiative Team RT, Team PM. Immune infiltrate analysis to reveal distinct immune classes for leiomyosarcomas. 2024 ASCO Annual Meeting.
113. Patel SR, Nash A, Ratan R, Somaiah N, Conley AP, Lewis VO, Wang W, Lin HY, Daw NC, Gill JB, Harrison DJ, Gorlick RG, Patel S, Livingston J. Harmonizing cancer care delivery for AYAs with osteosarcoma: Comparison of pediatric and medical oncology approaches in a single center. ASCO Annual Meeting.
114. Denu RA, Segura RL, Farooqi AS, Ingram D, Wani KM, Cai Y, Torres KE, Keung EZ, Roland CL, Somaiah N, Ying H, Huse JT, Rai K, Conley AP, Patel S, Wang W, Lazar AJ, Nassif Haddad EF. Impact of ATRX loss on survival and immune microenvironment in multiple sarcoma subtypes. 2024 ASCO Annual Meeting.

Book Chapters

1. Jensen, CT, Raval, B, Roland, CL, Bishop, AJ, Patel, S. Primary Retroperitoneal Tumors, 394-413, 2022.
2. Livingston JA, Conley AP, Ravi V, Patel SR. In: Chapter 42: Soft tissue and bone sarcomas, The MD Anderson Manual of Medical Oncology, 3rd edition. McGraw Hill, 2022.
3. Raval B, jensen C, Roland C, Bishop A, Patel SR. In: Primary Retroperitoneal Tumors In Oncologic Imaging. Silverman, 2nd Edition, 2018.
4. Ratan R, Patel S. Medical Oncology. In: Sarcomas: Evidence-Based Diagnosis and Management, 2018.
5. Kneisl JS, Rosenberg AE, Anderson PM, Antonescu CR, Bruland OS, Cooper K, Horvai AE, Holt GE, O’Sullivan B, Patel SR, Rose PS. In: AJCC Cancer Staging Manual. 8th. Springer, 471-786, 2017.
6. Albritton KH, Ferrari A, Patel SR, Wunder J. Soft Tissue Sarcomas. In: Cancer in Adolescents and Young Adults. Springer, 2016.
7. Patel SR. Soft tissue and bone sarcomas and tumors metastatic to bone. In: Harrison’s Principles of Internal Medicine. 20th. McGraw HIll, 2016.
8. Okuno S, Robinson S, Patel S. Medical Oncology principles for the Spine Oncology Surgeon. In: AOSpine Master Series, 2016.
9. Livingston JA, Conley A, Ravi V, Patel S. Soft-tissue and Bone Sarcomas. In: Medical Oncology - A comprehensive review, 2016.
10. Patel SR, Benjamin RS. Soft Tissue and Bone Sarcomas and Bone Metastases. In: Harrison's Principles of Internal Medicine. 19th. McGraw HIll, 2015.
11. Conley AP, Ravi V, Patel S. Targeted therapy in solid tumors: Sarcomas. In: Targeted therapies in Cancer, 2015.
12. Somaiah N, Gupta R, Patel S. In: Gastrointestinal Stromal Tumors in Textbook of Gastrointestinal Oncology, 2015.
13. Schmerling RA, Meirelles M, Buzaid AC, and Patel SR. Adult Soft Tissue Sarcoma. In: Brazilian Clinical Oncology Manual. Dendrix Edição e Design Ltda, 2014.
14. Schmerling RA, Buzaid AC, and Patel SR. Adult Bone Sarcoma. In: Brazilian Clinical Oncology Manual. Dendrix Edição e Design Ltda, 2014.
15. Ravi V, Pollock R, Patel SR. Soft-Tissue Sarcomas. In: 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, 2013.
16. Conley AP, Park M, Trent JC, Patel SR. In: Bone and soft-tissue sarcomas in Medical Oncology - A comprehensive review, 2013.
17. Ravi V, Patel SR. Adjuvant Chemotherapy for Soft-tissue Sarcomas. In: Surg Oncol Clin North Am, 2012.
18. Patel SR, Benjamin RS. Soft Tissue and Bone Sarcomas and tumors Metastic to Bone. In: Harrison’s Principles of Internal Medicine. McGraw HIll, 2011.
19. Patel SR, Benjamin RS. Soft Tissue and Bone Sarcomas and Tumors Metastatic to Bone. In: Harrison's Principles of Intrnal Medicine. 18th. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, 2011.
20. Raval B, Pollock RE, Guadagnolo A, Patel SR. Primary Retroperitoneal Tumors. In: Oncologic Imaging, 2011.
21. Patel SR, Benjamin RS. Soft Tissue and Bone Sarcomas and Tumors Metastatic to Bone. In: Harrison's Principles of Internal Medicine. 18th. McGraw-HIll, 2010.
22. Conley AP, Park M, Trent JC, Patel SR. In: Medical Oncology - A Comprehensive Review, 2010.
23. Ravi V, Patel SR. Desmoid Tumors. In: Up-To-Date, 2010.
24. Patel SR. Chemotherapy for Bone Tumors. In: ACS Clinical Atlas. Decker Publishing, 2009.
25. Araujo DM, Patel SR. Sarcoma - Diagnosis and Management. In: Clear Cell Saroma, 2008.
26. Patel SR, Benjamin RS. Soft tissue and bone sarcomas and tumors metastatic to bone. In: Harrison’s Principles of Internal Medicine. 17th. McGraw-Hill, 2007.
27. Blakely JL, Trent JC, Patel SR. Sarcomas. In: Medical Oncology - A comprehensive review, 879-902, 2006.
28. Patel SR, Benjamin RS. Soft tissue and bone sarcomas and bone metastases. In: Harrison’s Principles of Internal Medicine. 16th ed. McGraw-Hill, 558-562, 2004.
29. Patel SR, Benjamin RS. Evaluation and management of Bone Sarcomas. In: Clinical Practice of Hematology and Oncology: Presentations, Diagnosis and Treatment. W.B. Saunders, 1027-1037, 2003.
30. Patel SR, Benjamin RS. Sarcomas of the Gastrointestinal Tract. In: The Principles and Practice of Gastrointestinal Oncology. Oxford University Press, 834-838, 2003.
31. Patel SR. Systemic chemotherapy. In: Soft-tissue Sarcomas. BC Decker Inc. Publisher, 323-328, 2002.
32. Patel SR, Benjamin RS. Soft Tissue and Bone Sarcomas and Bone Metastases. In: Harrison’s Principles of Internal Medicine. 15th. McGraw-Hill, 625-627, 2001.
33. Hunt K, Sr P, Pollack A, Pollock RE. Sarcomas of Soft-Tissue and Bone. In: ACS Manual of Clinical Oncology. 3rd, 611-632, 2000.
34. Benjamin RS, Patel SR. Chemotherapy in the Treatment of Soft-Tissue Sarcomas. In: Tumors of the Soft Tissues. 2nd. Appleton & Lange, 553-563, 1998.
35. Patel SR, Benjamin RS. Sarcomas of Soft Tissue and Bone. In: Harrison’s Principles of Internal Medicine. 14th. McGraw-Hill, 611-614, 1997.
36. Daliani D, Patel SR. Sarcomas. In: Medical Oncology - A comprehensive Review, 511-530, 1995.
37. Patel SR, Benjamin RS. Osteosarcoma. In: Therapie-Konzepte. Springer-Verlag, 331-339, 1993.
38. Patel SR, Loprinzi CL. Breast Cancer. In: Cancer Chemotherapy and Biological Response Modifiers. Elsevier Science Publ B.V, 571-89, 1989.